

CITATION REPORT

List of articles citing

Estrogen plus progestin and the risk of coronary heart disease

DOI: 10.1056/nejmoa030808

New England Journal of Medicine, 2003, 349, 523-34.

Source: <https://exaly.com/paper-pdf/35713974/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1819	Testosterone and cardiovascular diseases. 2001 , 297-332		5
1818	Clinical approach to the patient with thrombosis. 2001 , 261-278		1
1817	Menopause and postmenopause. 2001 , 779-781		
1816	Hormone replacement therapy: what is the evidence today?. 2003 , 62, 508-11		
1815	Estrogen therapies, lipids, and the heart disease prevention controversy. 2003 , 5, 477-82		3
1814	Coronary heart disease: the female heart is vulnerable. 2003 , 46, 199-229		105
1813	Oestrogen plus progestin increases the risk of ischaemic stroke in postmenopausal women. 2003 , 7, 194-195		
1812	HRT: increased cardiac risk in diabetes. 2003 , 20, 268-269		0
1811	Implementing evidence-based practice. 2003 , 20, 269-270		1
1810	HT. A clinician demurs. 2003 , 80 Suppl 4, 15-8		2
1809	Effects of estrogen replacement on metabolic factors that influence physical performance in female hypogonadism. 2003 , 26, 902-10		1
1808	Agents that stabilise atherosclerotic plaque. 2003 , 12, 1681-92		1
1807	Old and new cardiovascular risk factors: from unresolved issues to new opportunities. 2003 , 4, 5-17		27
1806	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003 , 42, 1206-52		10207
1805	Cost of lost productive work time among US workers with depression. 2003 , 289, 3135-44		842
1804	Lipid profiles in women with 45,X vs 46,XX primary ovarian failure. 2003 , 290, 2127-8		39
1803	Herbal Medicine for Treating Menopausal Symptoms. 2003 , 9, 299-306		2

1802	A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O ₂ transporter. 2003 , 285, H549-61		39
1801	Hormone therapy: the European women's perspective. 2003 , 6, 337-346		38
1800	Hormone therapy and cardiovascular disease. <i>New England Journal of Medicine</i> , 2003 , 349, 2075-6; author reply 2075-6	59.2	1
1799	From presumed benefit to potential harm--hormone therapy and heart disease. <i>New England Journal of Medicine</i> , 2003 , 349, 519-21	59.2	69
1798	Hormone-replacement therapy and cardiovascular diseases. <i>New England Journal of Medicine</i> , 2003 , 349, 521-2	59.2	24
1797	Hormones and the heart: controversies and conundrums. 2003 , 88, 5609-10		4
1796	When defenses against fibroproliferation fail: spotlight on an axis of prophylaxis. 2003 , 168, 1141-2		6
1795	Menopause in crisis post-Women's Health Initiative? A view based on personal clinical experience. 2003 , 18, 2512-8		10
1794	Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. 2003 , 6, 302-313		62
1793	Oral contraceptives and endothelial function: harm or benefit?. 2003 , 21, 2227-30		4
1792	Alternative hormone replacement regimens: is there a need for further clinical trials?. 2003 , 14, 585-91		8
1791	Hormone replacement therapy update: who should we be prescribing this to now?. 2003 , 15, 459-64		13
1790	HRT: decide based on the evidence. 2003 , 28, 46-54		2
1789	Treatment of primary hyperparathyroidism. 2003 , 10, 394-399		6
1788	Osteoporosis treatment: the winds of change. 2003 , 14, 438-439		
1787	Time for new long-term trials of postmenopausal hormone therapies!. 2003 , 6, 265-267		4
1786	Hormone replacement therapy for women: the benefits, risks, and considerations for use in 2003. 2003 , 10, 400-418		1
1785	Hormone replacement therapy and the women's health initiative: the emperor has no clothes. 2004 , 10, 448-9		1

- 1784 Mammography and palpable breast abnormalities. **2004**, 140, 764; author reply 764
- 1783 Correction: Beyond Semmelweis: Moving Infection Control into the Community. **2004**, 140, 767
- 1782 Cost-Effectiveness of Cyclooxygenase-2 Inhibitors in Chronic Arthritis. **2004**, 140, 761 1
- 1781 The discrepancy between observational studies and randomized trials of menopausal hormone therapy. **2004**, 140, 764-5; author reply 765-6 10
- 1780 Diagnosis and management of adults with pharyngitis. **2004**, 140, 762; author reply 763
- 1779 Jaw droppers. **2004**, 328, 520
- 1778 Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis. **2004**, 140, 761; author reply 761-2 2
- 1777 Diagnosis and Management of Adults with Pharyngitis. **2004**, 140, 763
- 1776 Cardioprotection by chronic estrogen or superoxide dismutase mimetic treatment in the aged female rat. **2004**, 287, H165-71 42
- 1775 Delayed Drug Hypersensitivity Reactions. **2004**, 140, W-36
- 1774 Helicobacter pylori and idiopathic thrombocytopenic purpura. **2004**, 140, 766-7 44
- 1773 Delayed drug hypersensitivity reactions. **2004**, 140, W35; author reply W36 1
- 1772 Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. **2004**, 145, 5745-56 113
- 1771 Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. **2004**, 1, 82-8 12
- 1770 Tibolone activates nitric oxide synthesis in human endothelial cells. **2004**, 89, 4594-600 30
- 1769 Hormone therapy and Alzheimer's disease: benefit or harm?. **2004**, 5, 389-406 32
- 1768 Commentary: hormones and heart disease: do trials and observational studies address different questions?. **2004**, 33, 454-5 20
- 1767 [Postmenopausal hormone therapy]. **2004**, 129, 1689-93

1766	The lost promise of hormone replacement therapy and heart disease. 2004 , 4, 135-44	2
1765	Con: Sleep apnea does not cause cardiovascular disease. 2004 , 169, 148-9; discussion 150	19
1764	Genistein acutely stimulates nitric oxide synthesis in vascular endothelial cells by a cyclic adenosine 5'-monophosphate-dependent mechanism. 2004 , 145, 5532-9	90
1763	Consensus Recommendation on Hormone Therapy During the Climacterium and Postmenopause. 2004 , 64, 1024-1028	3
1762	The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002). 2004 , 13, 975-85	29
1761	Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. 2004 , 20, 1049-55	7
1760	Commentary: hormone replacement therapy and coronary heart disease: four lessons. 2004 , 33, 461-3	53
1759	Commentary: hazards of studying women: the oestrogen oestrogen/progesterone dilemma. 2004 , 33, 459-60	5
1758	Is the hormonal fountain of youth drying up?. 2004 , 59, 458-60	9
1757	Estrogen receptor-alpha agonists promote angiogenesis in human myometrial microvascular endothelial cells. 2004 , 11, 529-35	17
1756	Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. 2004 , 291, 1701-12	3160
1755	Gender determines the acute actions of genistein on intracellular calcium regulation in the guinea-pig heart. 2004 , 61, 66-76	18
1754	Inpatient diabetes control: rationale. 2004 , 27, 2074-80	7
1753	Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. 2004 , 109, 620-6	63
1752	Commentary: observation versus intervention--what's different?. 2004 , 33, 457-9	10
1751	Novel mechanisms responsible for postmenopausal hypertension. 2004 , 43, 918-23	162
1750	Hormone therapy: making decisions in the face of uncertainty. 2004 , 164, 2308-12	14
1749	Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. 2004 , 291, 1610-20	215

1748	Hormone replacement therapy and lung cancer risk: a case-control analysis. 2004 , 10, 113-23	151
1747	Gaps in the evidence for well-child care: a challenge to our profession. 2004 , 114, 1511-21	80
1746	Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. 2004 , 160, 1152-8	211
1745	The top 10 hot topics in aging. 2004 , 59, 24-33	48
1744	Estrogen plus progestin and risk of venous thrombosis. 2004 , 292, 1573-80	432
1743	Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. 2004 , 164, 482-4	58
1742	[Recommendations for estrogen and progestin replacement therapy in climacteric and postmenopause. 31. Professional Meeting of the Zurich Discussion Circle, October 2003]. 2004 , 44, 258-64	0
1741	Where are we now with hormone replacement therapy?. 2004 , 328, 357-8	17
1740	Synthesising licensing data to assess drug safety. 2004 , 328, 518-20	12
1739	Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?. 2004 , 19, 1697-704	31
1738	Sex hormones and membrane microviscosity in elderly women. 2004 , 109, e218; author reply e218	1
1737	Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. 2004 , 15, 1546-56	160
1736	Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon. 2004 , 4, 613-22	5
1735	Cardiovascular risk factors in middle-aged women and the association with use of hormone therapy: results from a population-based study of Swedish women. The Women's Health in the Lund Area (WHILA) Study. 2004 , 7, 274-83	13
1734	Role of the nonhuman primate for research related to women's health. 2004 , 45, 212-9	14
1733	Association of oestrogen receptor alpha gene polymorphism with the angiographic extent of coronary artery disease. 2004 , 25, 240-5	36
1732	A new slice of pie? Estrogen regulation of plasminogen activator inhibitor-1. 2004 , 95, 228-9	2
1731	Should progestins be blamed for the failure of hormone replacement therapy to reduce cardiovascular events in randomized controlled trials?. 2004 , 24, 1171-9	41

1730	National use of postmenopausal hormone therapy: annual trends and response to recent evidence. 2004 , 291, 47-53	712
1729	Evidence-based guidelines for cardiovascular disease prevention in women. 2004 , 109, 672-93	526
1728	Managing the menopause: BMS Council Consensus statement on HRT. 2004 , 10, 33-6	8
1727	Gender modulates cardiac phenotype development in genetically modified mice. 2004 , 63, 510-9	73
1726	Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. 2004 , 24, e29-50	55
1725	Hormone replacement therapy and cardiovascular disease: does route of administration and formulation matter?. 2004 , 124, 836-40	1
1724	Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. 2004 , 60, 541-9	42
1723	Sex hormone regulation of systemic endothelial and renal microvascular reactivity in type-2 diabetes: studies in gonadectomized and sham-operated Zucker diabetic rats. 2004 , 34, 349-57	22
1722	Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women. 2004 , 256, 437-45	4
1721	Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. 2004 , 256, 361-74	43
1720	Rationale, design and methods of the CASHMERE study. 2004 , 18, 131-8	14
1719	Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. 2004 , 19, 791-804	205
1718	The continuing evolution of women's health. 2004 , 19, 810-1	1
1717	Confronting the geriatrician's nightmare. 2004 , 52, 1393-4	13
1716	Side-effects of hormone replacement therapy and influence on pattern of use among women aged 45-64 years. The Norwegian Women and Cancer (NOWAC) study 1997. 2004 , 83, 850-6	19
1715	Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids. 2004 , 91, 476-81	16
1714	Effect of moderate alcohol consumption on plasma dehydroepiandrosterone sulfate, testosterone, and estradiol levels in middle-aged men and postmenopausal women: a diet-controlled intervention study. 2004 , 28, 780-5	70
1713	Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings. 2004 , 34, 631-6	46

1712	High-sensitivity C-reactive protein: Clinical importance. 2004 , 29, 439-493	14
1711	Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo. 2004 , 495, 179-84	10
1710	Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observational Study. 2004 , 93, 673-8	34
1709	Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women. 2004 , 94, 1205-8	11
1708	Is the WHI relevant to HRT started in the perimenopause?. 2004 , 24, 195-202	48
1707	The metabolic basis for the effects of HRT on coronary heart disease. 2004 , 24, 239-44	11
1706	Postmenopausal hormone replacement and cardiovascular disease: incorporating research into practice. 2004 , 33, 648-56	
1705	Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. 2004 , 19, 1270-5	54
1704	Menopausal hormone therapy: is there evidence for cardiac protection?. 2004 , 36, 617-23	2
1703	[Cardiovascular risks under hormone replacement therapy]. 2004 , 45, 826-34	
1702	[Cardiovascular risk in the "Women's Health Initiative". Much ado about nothing?]. 2004 , 45, 1315-7	
1701	[Endocrinology--I]. 2004 , 99, 293-308	
1700	Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study. 2004 , 2, 12-6	18
1699	[The women's health initiative and more]. 2004 , 33, 366-71	
1698	[When is hormone therapy useful?]. 2004 , 33, 372-7	
1697	Pharmacoepidemiology and drug safety. 2004 , 13, 49-64	
1696	Chronic disease prevention: public health potential and research needs. 2004 , 23, 3409-20	3
1695	Dietary phytoestrogens and health. 2004 , 65, 995-1016	422

- 1694 Oestrogen plus progestin significantly improves bone mineral density and reduces risk of fracture. **2004**, 8, 102-104
- 1693 Transdermal hormone therapy: gels and patches. **2004**, 7, 347-56 37
- 1692 Randomized trial of effects of estradiol in combination with either norethisterone acetate or trimegestone on lipids and lipoproteins in postmenopausal women. **2004**, 7, 292-300 13
- 1691 Guidelines for the hormone treatment of women in the menopausal transition and beyond. **2004**, 7, 8-11 33
- 1690 Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?. **2004**, 36, 402-13 38
- 1689 Hormone replacement therapy [practical recommendations]. **2004**, 7, 11-35 3
- 1688 Current controversies about combined hormone therapy and the relative risks to the breast and endometrium. **2004**, 7, 229-37
- 1687 Guidelines for hormone treatment of women in the menopausal transition and beyond. **2004**, 7, 333-7 41
- 1686 Estro-progestinici in menopausa: benefici e rischi. **2004**, 5, 104-110
- 1685 Risk factors for vascular dementia and Alzheimer disease. *Stroke*, **2004**, 35, 2620-2 6.7 262
- 1684 [AFSSAPS recommendations about menopause]. **2004**, 65, 179-83 0
- 1683 Mise au point actualis  sur le traitement hormonal substitutif de la m opause (THS) [D embre 2003]. **2004**, 3, 82-86
- 1682 Areas for future inquiry. *Endocrinology and Metabolism Clinics of North America*, **2004**, 33, 761-9 5.5
- 1681 Guidelines for the hormone treatment of women in the menopausal transition and beyond*1Position Statement by the Executive Committee of the International Menopause Society. **2004**,
- 1680 Genetic thrombophilia. **2004**, 31, 685-709, xi 10
- 1679 Heart failure in women. **2004**, 88, 1321-45, xii 63
- 1678 Management and prevention of cardiovascular disease in women. **2004**, 39, 873-84, xi
- 1677 Indications for hormone therapy: the post-Women's Health Initiative era. *Endocrinology and Metabolism Clinics of North America*, **2004**, 33, 691-715 5.5 5

1676	A wake-up call to advance women's health. 2004 , 14, 31-34		3
1675	Management of metabolic syndrome: aspirin. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004 , 33, 577-93, vii	5.5	17
1674	Progenitor cell dysfunction: a key trigger for atherosclerotic inflammation. 2004 , 1, 53-58		1
1673	Evidence-based guidelines for cardiovascular disease prevention in women. 2004 , 43, 900-21		80
1672	Risks of testosterone-replacement therapy and recommendations for monitoring. <i>New England Journal of Medicine</i> , 2004 , 350, 482-92	59.2	566
1671	New progestogens: a review of their effects in perimenopausal and postmenopausal women. 2004 , 21, 865-83		79
1670	Sexual dysfunction in the older woman: an overview of the current understanding and management. 2004 , 21, 655-75		53
1669	Strategies for managing breast cancer risk after the menopause. 2004 , 3, 289-307		3
1668	17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. 2004 , 95, 692-9		270
1667	Measuring hot flashes: summary of a National Institutes of Health workshop. 2004 , 79, 777-81		51
1666	Risques et bénéfices du THS. 2004 , 4, 49-53		
1665	Osteogenic regulation of vascular calcification: an early perspective. 2004 , 286, E686-96		290
1664	[Effects of HRT on the risks of breast cancer and cardiovascular disease: the validity of the epidemiological evidence]. 2004 , 32, 382-90		3
1663	[Up-to-date clarification on the menopause hormonal substitutive treatment (HRT) December 2003]. 2004 , 32, 571-5; discussion 569-70		
1662	Opposition to unpopular research results: Finnish professional reactions to the WHI findings. 2004 , 69, 283-91		12
1661	Serum lipids and estrogen receptor gene polymorphisms in male-to-female transsexuals: effects of estrogen treatment. 2004 , 15, 231-237		21
1660	A wake-up call to advance women's health. 2004 , 14, 31-4		6
1659	Hormones, menopause, and heart disease: making sense of the Women's Health Initiative. 2004 , 14, 212-9		18

1658	The WHI and the brain: what have we learned?*. 2004 , 2, 71-75	1
1657	Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. 2004 , 15, 66-72	46
1656	Progestogen therapies: differences in clinical effects?. 2004 , 15, 277-85	38
1655	Potent opioids for chronic musculoskeletal pain: flying blind?. 2004 , 109, 207-209	72
1654	Estrogens and breast cancer: does timing really matter?. 2004 , 57, 763-5	1
1653	Hormone replacement therapy and cardiovascular disease. 2004 , 1262, 523-526	
1652	Critique of the evidence from large trials of hormone replacement therapy. 2004 , 1266, 139-150	3
1651	Treating menopause in the 21st century—where do we go from here?. 2004 , 1266, 3-9	
1650	HRT and heart disease: problems and prospects. 2004 , 47, 255-8	7
1649	Guidelines for the hormone treatment of women in the menopausal transition and beyond. Position statement by the Executive Committee of the International Menopause Society. 2004 , 48, 27-31	14
1648	WHI estrogen-only arm is canceled. 2004 , 48, 3-4	4
1647	The turbulent seas of women's health—who is the beneficiary?. 2004 , 48, 5-7	3
1646	An evaluation of the contents and quality of menopause information on the World Wide Web. 2004 , 49, 276-82	32
1645	Polycystic ovary syndrome: what is it and how should we treat it?. 2004 , 144, 4-6	7
1644	Physical activity decreases cardiovascular disease risk in women: review and meta-analysis. 2004 , 26, 407-18	211
1643	Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy. 2004 , 7, 131-6	1
1642	Where are we now with hormone replacement therapy?. 2004 , 12, 200-3	1
1641	Hormone replacement therapy and atherosclerosis—postmenopausal women and HRT: the fallen myth of the cardiovascular protective effects of hormone replacement therapy. 2004 , 1262, 519-522	

1640	Coronary artery bypass graft surgery in women. 2004 , 18, 344-52	4
1639	Estrogen and progestogen therapy in postmenopausal women. 2004 , 81, 231-41	6
1638	Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. 2004 , 82, 391-7	77
1637	The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. 2004 , 81, 1498-501	119
1636	Estrogen and progestogen therapy in postmenopausal women. 2004 , 82 Suppl 1, S70-80	6
1635	HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. 2004 , 82, 1540-9	14
1634	Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care. 2004 , 170, 1388-9	8
1633	Health behaviors and other characteristics of women on hormone therapy: results from the Third National Health and Nutrition Examination Survey, 1988-1994. 2004 , 11, 536-42	15
1632	Estrogens, lipoproteins, and cardiovascular risk factors: an update following the randomized placebo-controlled trials of hormone-replacement therapy. 2004 , 15, 459-67	27
1631	Focusing on inflammation in the treatment of atherosclerosis. 2004 , 12, 194-200	15
1630	Women's Health Initiative perspective: what does it really mean to the rheumatologist?. 2004 , 10, 97-9	
1629	Current World Literature. 2004 , 15, 469-474	
1628	Neuroendocrine changes in sleep apnea. 2004 , 10, 475-81	22
1627	Estrogen receptor polymorphisms in common disease: recent developments. 2004 , 11, 141-146	
1626	Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care. 2004 , 170, 1535-7	19
1625	Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. 2004 , 32, 2443-9	189
1624	Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. 2004 , 11, 405-15	40
1623	Ménopause en 2004 : le « traitement hormonal substitutif » n'est plus ce qu'il était. 2004 , 25, 806-815	6

1622	Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. 2004 , 26, 967-73	12
1621	Hormone Therapy: a practical guide to risk assessment for short-term symptomatic treatment of menopausal symptoms. 2004 , 46, 37-42	1
1620	Use and perception of hormone therapy following media reports of the Women's Health Initiative: a survey of Australian WISDOM participants. 2004 , 7, 143-52	7
1619	Publishing the results of the estrogen-only arm of WHI. 2004 , 7, 117-9	2
1618	Isoflavones and coronary heart disease. 2004 , 187-214	1
1617	Hormone therapy use after the Women's Health Initiative. 2004 , 7, 138-42	44
1616	Sex differences in carotid plaque and stenosis. <i>Stroke</i> , 2004 , 35, 477-81	6.7 115
1615	Current controversies regarding the cardiovascular effects of hormone therapy. 2004 , 47, 489-99	10
1614	Observations and outcomes: a comment on "seasonal variation in AF-related admissions to a coronary care unit in a 'hot' climate: fact or fiction?". 2004 , 19, 142-4	
1613	The epidemiology of age-related macular degeneration. 2004 , 44, 17-39	85
1612	Measuring Hot Flashes: Summary of a National Institutes of Health Workshop. 2004 , 79, 777-781	81
1611	Hormone replacement therapy and age-related brain shrinkage: regional effects. 2004 , 15, 2531-4	36
1610	Views on recent trials and the future of hormonal therapy. 2004 , 47, 424-7	1
1609	Mise au point actualis� sur le traitement hormonal substitutif de la m�opause (THS) d�embre 2003. 2004 , 32, 571-575	
1608	HRT Reconsidered: What should you tell patients about it now?. 2004 , 104, 51-3	7
1607	Psychological treatments. 2004 , 59, 869-878	226
1606	Postmenopausal estrogen for treatment of hot flashes: clinical applications. 2004 , 291, 1621-5	22
1605	[Controversies on the arterial risk of hormone substitution treatment]. 2004 , 59, 63-70	

1604	Diagnosis and management of adults with pharyngitis. 2004 , 140, 763; author reply 763	
1603	High-sensitivity C-reactive protein: Clinical importance. 2004 , 29, 439-493	30
1602	Correction: Responsiveness of Thrombotic Thrombocytopenic Purpura to Rituximab and Cyclophosphamide. 2004 , 140, 767	
1601	Can drospirenone with 17-beta estradiol safely reduce blood pressure in hypertensive postmenopausal women?. 2005 , 1, 72-3	1
1600	Menopausal hormone therapy. 2005 , 27, 137-62	23
1599	Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. 2005 , 12, 69-77	35
1598	Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. 2005 , 12, 366-73	39
1597	Endothelium-dependent dilatory effects of 3alpha-OH-tibolone in gracilis muscle arterioles of the female Wistar rat. 2005 , 12, 340-7	3
1596	Transdermal drug delivery: clinical considerations for the obstetrician-gynecologist. 2005 , 105, 953-61	22
1595	Effects of soy isoflavones on endothelial function in healthy postmenopausal women. 2005 , 12, 299-307	79
1594	Hormone use and patient concerns after the findings of the Women's Health Initiative. 2005 , 12, 399-404	35
1593	Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women. 2005 , 12, 526-35	19
1592	Postmenopausal hormone therapy and cardiovascular disease: one view of the elephant. 2005 , 12, 357-8	2
1591	Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial. 2005 , 12, 728-33	30
1590	The new hormone therapy problem: do we solve it with long-cycle progesterone therapy?. 2005 , 12, 664-7	
1589	Effects of tibolone on bone quality in ovariectomized monkeys. 2005 , 12, 613-8	4
1588	The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. 2005 , 142, 953-62	415
1587	Management of postmenopausal hot flashes with venlafaxine hydrochloride: a randomized, controlled trial. 2005 , 105, 161-6	162

1586	Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. 2005 , 12, 186-92	60
1585	Postmenopausal hormone replacement therapy after the Women's Health Initiative. 2005 , 18, 30-7; quiz 39-40	
1584	Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine. 2005 , 12, 92-8	14
1583	Prevention: the key to reducing cardiovascular disease risk in women. 2005 , 20, 433-41	1
1582	Impact of hormone replacement on myocardial fatty acid metabolism: potential role of estrogen. 2005 , 12, 574-81	37
1581	Actualité sur la ménopause. Données de la médecine factuelle (« evidence based medicine »). 2005 , 2, 90-101	
1580	Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. 2005 , 1052, 43-56	76
1579	Recognition and prevention of cardiovascular disease in women. 2005 , 31, 255-61	2
1578	Author's reply. 2005 , 7, 212-213	
1577	Authors' reply. 2005 , 7, 213-214	
1576	Group B streptococcal screening. 2005 , 7, 213-213	
1575	Reply. 2005 , 192, 334	0
1574	The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. 2005 , 193, 1384-94	9
1573	Discussion. 2005 , 193, 556-557	3
1572	Closing Discussion by Dr Williams. 2005 , 193, 557-558	0
1571	The impact of clinical trials on the use of hormone replacement therapy. A population-based study. 2005 , 20, 1026-31	43
1570	Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. 2005 , 112, 692-5	22
1569	Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. 2006 , 113, 5-14	49

1568	Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians. 2005 , 4, 1-6	
1567	Clinical appraisal of the Women's Health Initiative. 2005 , 31, 80-93	5
1566	Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. 2005 , 62, 64-73	192
1565	Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. 2005 , 62, 228-35	33
1564	Bias as a threat to the validity of cancer molecular-marker research. 2005 , 5, 142-9	403
1563	Hormone replacement therapy in women with spinal cord injury - a survey with literature review. 2005 , 43, 67-73	3
1562	Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens. 2005 , 28 Suppl 1, S172-7	23
1561	Statistical issues arising in the Women's Health Initiative. 2005 , 61, 899-911; discussion 911-41	49
1560	Rejoinder. 2005 , 61, 935-941	
1559	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 911-912	1
1558	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 914-918	1
1557	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 918-920	2
1556	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 920-921	5
1555	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 922-930	22
1554	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 930-933	
1553	Discussion on "Statistical Issues Arising in the Women's Health Initiative". 2005 , 61, 933-935	
1552	When practices, promises, profits, and policies outpace hard evidence: the post-menopausal hormone debate. 2005 , 61, 159-79	9
1551	Ageing, traumatic injury, and estrogen treatment. 2005 , 40, 549-55	64

1550	Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. 2005 , 1038, 216-22	74
1549	La terapia hormonal sustitutiva: mandan las evidencias. 2005 , 14, 46-51	
1548	The relationship between albuminuria and hormone therapy in postmenopausal women. 2005 , 45, 1019-25	45
1547	Report from the Rockefeller Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. 2005 , 75, 68-76	42
1546	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. 2005 , 52, 1655-64	35
1545	Lipids and lipoproteins in women. 2005 , 30, 368-74; quiz 429-30	7
1544	Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. 2005 , 30, 356-67	32
1543	[Role of hormone-replacement therapy for prevention of coronary artery disease in women]. 2005 , 94 Suppl 3, III/74-8	1
1542	Is "cardiovascular protection" by estrogens due to inhibition of the sympathetic nervous system?. 2005 , 15, 186-8	
1541	Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians. 2005 , 4, 1-6	
1540	Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre- and post-menopausal women. 2005 , 93, 277-87	19
1539	The Women's Health Initiative study: perspectives and implications for clinical practice. 2005 , 6, 93-9	5
1538	An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. 2005 , 5, 12	63
1537	Changes in elderly women's health-related quality of life following discontinuation of hormone replacement therapy. 2005 , 5, 7	5
1536	Menopausal hormone therapy: currently no evidence for cardiac protection. 2005 , 44, 625-9	7
1535	Menopause, micronutrients, and hormone therapy. 2005 , 81, 1223S-1231S	11
1534	After the Women's Health Initiative--Menopausal Women and Hormone Therapy. 2005 , 7, 751	
1533	Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM. 2004 , 6, S27-35	30

1532	Women, hormones, and clinical trials: a beginning, not an end. 2005 , 99, 381-3	27
1531	Women's Health Initiative: Statistical Aspects and Selected Early Results. 2005 , 1-11	
1530	Women's Health Initiative: Statistical Aspects and Selected Early Results. 2005 ,	
1529	Komplementärmedizin - quo vadis? Soll sich die FMH für die Erhaltung oder sogar für die Förderung komplementärmedizinischer Angebote bei ihren Mitgliedern einsetzen?. 2005 , 17, 14-18	0
1528	Women's Health Initiative Hormone Therapy Trials. 2005 , 1-10	
1527	Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport. 2005 , 537-61	14
1526	Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial. 2005 , 60, 460-2	28
1525	Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. 2005 , 112, 1979-84	89
1524	Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. 2005 , 23, 5126-37	244
1523	Hormone replacement use, arterial distensibility, cardiac structure and circadian blood pressure profile in menopausal women. 2005 , 14, 12-20	6
1522	Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. 2005 , 288, H1627-32	50
1521	The prevention of osteoporotic fractures. 2005 , 87, 1320-7	17
1520	Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy. 2005 , 11, 152-6	8
1519	Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. 2005 , 105, 1074-83	151
1518	Iron stores and vascular function in voluntary blood donors. 2005 , 25, 1577-83	75
1517	Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. 2005 , 162, 404-14	231
1516	Navigating the journey to menses cessation: a study of change in an emancipatory context. 2005 , 23, 34-50; discussion 51-3	5
1515	A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators. 2005 , 80, 1253-60	8

1514	[Hormone therapy and menopause]. 2005 , 130, 829-34		1
1513	Coronary heart disease in women: what do we know now?. 2005 , 1, 617-28		2
1512	HDL therapy: the next big step in the treatment of atherosclerosis?. 2005 , 1, 767-73		1
1511	Culture and symptom reporting at menopause. 2005 , 11, 495-512		182
1510	Does hormone replacement therapy have a future?. 2005 , 1, 5-8		
1509	Lower doses of oral estrogen and progestogens as treatment for postmenopausal women. 2005 , 23, 188-95		12
1508	Hormone replacement use and cardiovascular function and structure in postmenopausal women. 2005 , 14, 3-5		0
1507	A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus. 2005 , 21, 2051-61		4
1506	Postmenopausal hormone therapy and informed consent: a call for common sense. 2005 , 14, 592-4		
1505	Hormone therapy and cardiovascular disease--still much to be learnt. 2005 , 20, 116-20		7
1504	Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. 2005 , 21, 135-40		18
1503	The rise and fall of menopausal hormone therapy. 2005 , 26, 115-40		56
1502	Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. 2005 , 111, 1492-8		113
1501	Sex steroids, cardiovascular disease, and hypertension: unanswered questions and some speculations. 2005 , 45, 170-4		126
1500	Commentary on Navigating the Journey to Menses Cessation 2005 , 23, 51-53		1
1499	Estrogen treatment abrogates neointima formation in human C-reactive protein transgenic mice. 2005 , 25, 2094-9		28
1498	Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. <i>Stroke</i> , 2005 , 36, 1316-29	6.7	226
1497	State of the science: hot flashes and cancer. Part 2: management and future directions. 2005 , 32, 969-78		7

1496	Invited commentary: Acne in adolescence--protecting the heart but damaging the prostate later in life?. 2005 , 161, 1102-6		7
1495	Menopausal symptom management and prevention counseling after the Women's Health Initiative among women seen in an internal medicine practice. 2005 , 14, 507-14		24
1494	Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trials. 2005 , 104, 143-7		8
1493	William M. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. <i>Stroke</i> , 2005 , 36, 875-9	6.7	57
1492	Gender differences in outcome of conservatively treated patients with asymptomatic high grade carotid stenosis. <i>Stroke</i> , 2005 , 36, 1178-83	6.7	52
1491	Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy. 2005 , 26, 1358-61		42
1490	Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. 2005 , 20, 2052-60		78
1489	Levels of serum C-reactive protein during oral and transdermal estradiol in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy. 2005 , 90, 142-6		14
1488	Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. 2005 , 90, 1202-9		84
1487	Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. 2005 , 90, 855-63		39
1486	Can a marker be a surrogate for development of cancer, and would we know it if it exists?. 2005 , 166, 99-112		3
1485	Treatment of menopausal symptoms: what shall we do now?. 2005 , 366, 409-21		98
1484	The lady aspirin for cardiovascular disease. 2005 , 366, 1148-50		9
1483	Isoflavonas y menopausia. 2005 , 32, 92-98		
1482	[Osteoporosis and hormone replacement therapy]. 2005 , 34, 379-84		1
1481	Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. 2005 , 83, 558-66		85
1480	Short-term effect of transdermal estrogen on autonomic nervous modulation in postmenopausal women. 2005 , 84, 1477-83		6
1479	A critique of the Women's Health Initiative hormone therapy study. 2005 , 84, 1589-601		48

- 1478 Discussion on "Statistical Issues Arising in the Women's Health Initiative". **2005**, 61, 912-914
- 1477 [Update on menopause treatments, after recent controversies]. **2005**, 66, 30-2
- 1476 Effects of hormone replacement on progression of coronary calcium as measured by electron beam tomography. **2005**, 14, 410-7 29
- 1475 Coronary heart disease prevention in menopausal women. **2005**, 6, 695-705
- 1474 Abstracts of the 11th World Congress on the Menopause. **2005**, 8 Suppl 2, 1-238
- 1473 Hormone therapy for younger postmenopausal women: how can we make sense out of the evidence?. **2005**, 8, 307-10 6
- 1472 KEEPS: The Kronos Early Estrogen Prevention Study. **2005**, 8, 3-12 256
- 1471 Radiotherapy for breast cancer. **2005**, 97, 406-7 20
- 1470 No estrogen-like effects of an isopropanolic extract of *Rhizoma Cimicifugae racemosae* on uterus and vena cava of rats after 17 day treatment. **2005**, 97, 271-7 26
- 1469 Differential estrogen signaling in endothelial cells upon pulsed or continuous administration. **2005**, 50, 247-58 23
- 1468 Nitric oxide in postmenopausal women taking three different HRT regimens. **2005**, 50, 52-7 9
- 1467 Osteoporosis beliefs and antiresorptive medication use. **2005**, 50, 196-208 32
- 1466 Bone health across the generations: a primer for health providers concerned with osteoporosis prevention. **2005**, 50, 1-7 4
- 1465 *Cimicifuga racemosa* dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. **2005**, 51, 397-404 99
- 1464 Women's views of the climacteric at the time of low menopausal hormone use, Estonia 1998. **2005**, 51, 413-25 6
- 1463 Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women. **2005**, 52, 52-9 12
- 1462 Hormone replacement therapy in Germany: determinants and possible health-related outcomes. Results of National Health Surveys from 1984 to 1999. **2005**, 52, 223-34 12
- 1461 Guidelines for hormone treatment of women in the menopausal transition and beyond. **2005**, 51, 15-20 11

1460	The woman patient after WHI. 2005 , 51, 29-37	6
1459	Menopause and HRT--the state of the art in Europe. 2005 , 51, 40-7	6
1458	WHI and aftermath: looking beyond the figures. 2005 , 51, 48-50	2
1457	Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones. 2005 , 51, 51-63	25
1456	Controversies about HRT--lessons from monkey models. 2005 , 51, 64-74	81
1455	Appropriate use of hormones should alleviate concerns of cardiovascular and breast cancer risk. 2005 , 51, 98-109	7
1454	Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1. 2005 , 52, 87-101	14
1453	Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]. 2005 , 52, 286-95	14
1452	New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. 2005 , 52, 1-10	56
1451	Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. 2005 , 52, 11-7	61
1450	Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. 2005 , 49, 472-93	96
1449	Gender and estrogen supplementation increases severity of experimental choroidal neovascularization. 2005 , 80, 413-23	27
1448	Saliva versus serum estradiol: implications for research studies using postmenopausal women. 2005 , 29, 727-32	29
1447	After the Women's Health Initiative: decision making and trust of women taking hormone therapy. 2005 , 15, 187-95	25
1446	Principles of cancer prevention. 2005 , 21, 229-35	5
1445	Estrogen replacement therapy and retinal vascular caliber. 2005 , 112, 553-8	24
1444	Prevention of Breast Cancer. 2005 , 58-73	
1443	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. 2005 , 149, 408-13	97

1442	Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials. 2005 , 150, 1260-7	39
1441	Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. 2005 , 18, 797-804	63
1440	Estrogen with and without progestin: benefits and risks of short-term use. 2005 , 118 Suppl 12B, 79-87	17
1439	The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms. 2005 , 118 Suppl 12B, 155-62	6
1438	Other complementary and alternative medicine modalities: acupuncture, magnets, reflexology, and homeopathy. 2005 , 118 Suppl 12B, 109-17	37
1437	Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. 2005 , 118 Suppl 12B, 64-73	138
1436	Long term hormone therapy for perimenopausal and postmenopausal women. 2005 , CD004143	57
1435	Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. 2005 , 28, 473-93	8
1434	Role of Estrogens in Vascular Disease in Diabetes. 2005 , 129-165	
1433	Increased carotid atherosclerosis in andropausal middle-aged men. 2005 , 45, 1603-8	126
1432	The ethics of placebo-controlled trials: the case of asthma. 2005 , 115, 1228-34	9
1431	Neuroendocrinology of female aging. 2005 , 2, 41-56	42
1430	Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease. 2005 , 22, 823-44	17
1429	Atherosclerosis: Diet and Drugs. 2005 ,	2
1428	A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. <i>New England Journal of Medicine</i> , 2005 , 352, 1293-304	59.2 1488
1427	Pharmacology of estrogens and progestogens: influence of different routes of administration. 2005 , 8 Suppl 1, 3-63	544
1426	Cardiovascular Biomarkers. 2006 ,	2
1425	Homocysteine lowering with folic acid and vitamin B supplements: effects on cardiovascular disease in older adults. 2006 , 23, 491-502	8

1424	Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. 2006 , 3, 254-69	59
1423	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. 2006 , 27, 1341-81	981
1422	Hormone replacement therapy in menopausal women: Past problems and future possibilities. 2006 , 22, 564-77	15
1421	Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. 2006 , 15, 1091-103	42
1420	Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?. 2006 , 24, 1079-86	16
1419	Hormone therapy: maximizing the benefits. 2006 , 22, 160-2	4
1418	From the challenge to the reassessment of the Women's Health Initiative: a personal initiative for women's health. 2006 , 22, 115-6	2
1417	The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. 2006 , 22, 303-17	20
1416	The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. 2006 , 24, 3576-82	166
1415	[Hypertension in women after menopause]. 2006 , 35, 1055-60	1
1414	[Hormone replacement therapy in the management of postmenopausal osteoporosis and prevention of fracture risk]. 2006 , 35, 1557-63	10
1413	Which progestogen is more likely to increase the risk of fatal myocardial infarction: a combination of epidemiological and trial evidence. 2006 , 54, 154-63	6
1412	Estrogen receptor-alpha variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study. 2006 , 185, 210-8	46
1411	Menopausal estrogen therapy counteracts normal aging effects on intima thickness, media thickness and intima/media ratio in carotid and femoral arteries. An investigation using noninvasive high-frequency ultrasound. 2006 , 189, 387-92	32
1410	[Skin and menopause]. 2006 , 67, 575-80	10
1409	Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. 2006 , 66, 191-221	43
1408	Current status of combined hormone replacement therapy in clinical practice. 2006 , 6 Suppl 2, S51-7	9
1407	Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. 2006 , 6 Suppl 2, S58-64	23

1406	Assessing drug risks and benefits: lessons from postmenopausal hormone therapy studies. 2006 , 6 Suppl 2, S65-70	1
1405	[Guidelines on the management of stable angina pectoris. Executive summary]. 2006 , 59, 919-70	22
1404	A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. 2006 , 46, 29-36	15
1403	Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. 2006 , 31, 659-74	157
1402	Hypertension, menopause, and coronary artery disease risk in the Women's Ischemia Syndrome Evaluation (WISE) Study. 2006 , 47, S50-8	76
1401	Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (<i>Humulus lupulus</i> L.). 2006 , 34, 1152-9	86
1400	Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. 2006 , 119, 167.e1-8	17
1399	Cardiopulmonary rehabilitation and cancer rehabilitation. 1. Cardiac rehabilitation review. 2006 , 87, S46-56	4
1398	Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative. 2006 , 152, 170-6	53
1397	Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. 2006 , 151, 1032.e1-7	32
1396	Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. 2006 , 85, 667-73	12
1395	Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. 2006 , 85, 979-88	10
1394	Estrogen and progestogen therapy in postmenopausal women. 2006 , 86, S75-88	3
1393	Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative. 2006 , 16 Suppl A, S98-102	20
1392	Involvement of phosphoinositide-3-kinase and phospholipase C transduction systems in the non-genomic action of progesterone in vascular tissue. 2006 , 38, 288-96	15
1391	The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. 2006 , 6, 313-8	10
1390	Effect of the cessation of long-term hormone replacement therapy on plasma plasminogen activator inhibitor-1 and fibrinogen. 2006 , 125, 217-20	3
1389	Hormone therapies in women aged 40 and older: prevalence and correlates of use. 2006 , 53, 65-76	8

1388	Menopausal symptoms after cessation of hormone replacement therapy. 2006 , 53, 356-61	39
1387	Use of hormones in the menopausal transition period in the Netherlands between 1993 and 1997. 2006 , 53, 462-75	11
1386	Risk of stroke and hormone replacement therapy. A prospective cohort study. 2006 , 54, 11-8	19
1385	Results from the Estonian postmenopausal hormone therapy trial [SRCTN35338757]. 2006 , 55, 162-73	43
1384	Latin American position on the current status of hormone therapy during the menopausal transition and thereafter. 2006 , 55, 5-13	4
1383	Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. 2006 , 54, 372-9	12
1382	Nongenomic actions of estrogens: exciting opportunities for pharmacology. 2006 , 54, 321-6	8
1381	Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. 2006 , 55, 297-307	30
1380	Interpreting observational studies -- look before you leap. 2006 , 59, 763-4	3
1379	How to evaluate the risk-benefit ratio of the low-dose hormone replacement therapy?. 2006 , 102, 256-60	4
1378	Retinal vessel diameter. 2006 , 113, 886-7.e1; author reply 887	3
1377	Author Reply. 2006 , 113, 885-886	
1376	Signal transduction pathways involved in non-genomic action of estrone on vascular tissue. 2006 , 71, 857-64	6
1375	Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. 2006 , 17, 101-9	41
1374	Women's Health Care in the Incarcerated Setting. 2006 , 144-163	1
1373	. 2006 ,	21
1372	Study Designs Available for Pharmacoepidemiology Studies. 17-28	3
1371	Gynecologists and estrogen: an affair of the heart. 2006 , 49, 115-30	10

1370	Hormones, Metabolism, Aging and Men's Health. 225-288	11
1369	Nuclear receptor mediated gene regulation through chromatin remodeling and histone modifications. 2006 , 53, 157-72	69
1368	Comment: Causal Inference in the Medical Area. 2006 , 21, 310	4
1367	Folate Intake and the Risk of Incident Hypertension Among US Women. 2006 , 2006, 23-24	
1366	Hormonal therapy: does it increase or decrease cardiovascular risk?. 2006 , 61, 673-81	17
1365	Estradiol and phytoestrogens differently influence the rodent postmenopausal mammary gland. 2006 , 13, 72-9	17
1364	Paradigm shifts in the approach to women's health care. 2006 , 19, 50, 52-3, 55	
1363	Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. 2006 , 296, 1877-84	51
1362	Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. 2006 , 166, 399-404	18
1361	Prevalence and causes of persistent use of hormone replacement therapy among postmenopausal women: a follow-up study. 2006 , 13, 109-12	15
1360	Cardiovascular Disease. 2006 , 28, S81-S86	
1359	Pain: clinical and imaging risk factors. 2006 , 31, E1-3	
1358	Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. 2006 , 13, 340-67; quiz 368-9	159
1357	Peering through the darkened glass: success and disappointment in the management of cardiovascular risk. 2006 , 17, 615-8	
1356	Postmenopausal hormone therapy: new questions and the case for new clinical trials. 2006 , 13, 139-47	64
1355	Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women. 2006 , 13, 517-27	18
1354	The role of phytochemicals in menopause: a new actor on the scene of alternative treatment options. 2006 , 13, 724-6	
1353	Cardiovascular risk and hormone replacement therapy. 2006 , 18, 658-65	7

1352	Women and hypertension: what did we learn from the Women's Health Initiative?. 2006 , 14, 267-75	38
1351	Hormone replacement therapy in endometrial cancer survivors: new perspectives after the heart and estrogen progestin replacement study and the women's health initiative. 2006 , 10, 92-101	3
1350	Impact of hormone therapy on false-positive recall and costs among women undergoing screening mammography. 2006 , 44, 62-9	7
1349	Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. 2006 , 13, 80-6	18
1348	What is the effect of estrogen on blood pressure after menopause?. 2006 , 13, 331-3	12
1347	Oxidative stress explains differences in large elastic artery compliance between sedentary and habitually exercising postmenopausal women. 2006 , 13, 951-8	39
1346	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. 2006 , 12, 315-37	54
1345	Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. 2006 , 8, 538-54	363
1344	Postmenopausal hormone therapy: who now takes it and do they differ from non-users?. 2006 , 46, 128-35	16
1343	Understanding the oestrogen action in experimental and clinical atherosclerosis. 2006 , 20, 539-48	23
1342	Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006. 2006 , 16 Suppl 2, 479-91	2
1341	Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. 2006 , 21, 363-6	244
1340	Testosterone treatment comes of age: new options for hypogonadal men. 2006 , 65, 275-81	111
1339	Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. 2006 , 259, 199-208	25
1338	Traitement hormonal et ostéoporose postménopausique. 2006 , 73, 812-816	
1337	Pitfalls of the WHIs: Women's Health Initiative. 2006 , 1092, 331-40	16
1336	Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease. 2006 , 1089, 444-53	15
1335	Hormone therapy in the WHI era. 2006 , 46, 84-91	13

1334	Postmenopausal hormone therapy increases use of health services: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757]. 2006 , 195, 62-71	7
1333	Fallout from the Women's Health Study: A Short-lived Vindication for Feminists and the Resurrection of Hormone Therapies. 2006 , 54, 401-411	8
1332	Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. 2006 , 273, 268-73	10
1331	Klinische Bedeutung von gestagenen Partialwirkungen. 2006 , 4, 52-64	1
1330	Herz-Kreislauf-Erkrankungen. 2006 , 39, 354-361	
1329	Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature. 2006 , 17, 29-40	42
1328	Aromatase inhibitors as adjuvant treatment of breast cancer. 2006 , 57, 53-61	17
1327	Opvliegers. 2006 , 49, 951-956	
1326	Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. 2006 , 97, 520-7	44
1325	Menopause: evidence-based practice. 2006 , 20, 799-839	44
1324	Estrogen replacement and cardiomyocyte protection. 2006 , 16, 69-75	42
1323	'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease. 2006 , 112, 529-52	67
1322	Sex dimorphism in cardiac pathophysiology: experimental findings, hormonal mechanisms, and molecular mechanisms. 2006 , 111, 434-75	48
1321	A course designed for undergraduate biochemistry students to learn about cultural diversity issues. 2006 , 34, 326-31	3
1320	Exploring the role of medical and consumer literature in the diffusion of information related to hormone therapy for menopausal women. 2006 , 57, 974-988	6
1319	Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. 2006 , 21, 2715-20	44
1318	Activation of nitric oxide synthesis in human endothelial cells using nomegestrol acetate. 2006 , 108, 969-78	16
1317	[Hormone replacement therapy for internal risk patients]. 2006 , 46, 174-90	5

1316	The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. 2006 , 27, 746-55	60
1315	Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. 2006 , 27, 2046-53	30
1314	HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?. 2006 , 21, 1668-71	23
1313	Arzoxifene: the development and clinical outcome of an ideal SERM. 2006 , 15, 317-26	26
1312	Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating Fas and Fas ligand expression. 2006 , 91, 4995-5001	25
1311	[Patient-relevant end points: present state of the discussion at the Institute for Quality and Cost-Effectiveness in Public Health]. 2006 , 131, S16-20	2
1310	Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. 2006 , 22, 1575-85	27
1309	Current state of hormone replacement therapy: the case for using trimegestone. 2006 , 2, 539-50	1
1308	No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. 2006 , 21, 1635-42	10
1307	Cyclooxygenases regulation by estradiol on endothelium. 2006 , 12, 205-15	31
1306	Estrogen and salt sensitivity in the female mRen(2). Lewis rat. 2006 , 291, R1557-63	42
1305	The etiology of hypertension in the metabolic syndrome part four: the systemic perspective--the role of the neuroendocrine and immune systems, and the challenge of integration. 2006 , 4, 349-81	3
1304	Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. 2006 , 163, 589-99	135
1303	Testosterone replacement therapy for late-onset hypogonadism. 2006 , 3, 260-7	29
1302	Aspects of the design and analysis of high-dimensional SNP studies for disease risk estimation. 2006 , 7, 339-54	29
1301	Potentially inappropriate prescribing for elderly patients in 2 outpatient settings. 2006 , 21, 162-8	18
1300	A study of women on long-term hormone replacement therapy and their attitude to suggested cessation. 2006 , 9, 459-63	14
1299	Cardiovascular health and the menopause: the gynecologist as the patients' interface. 2006 , 9 Suppl 1, 6-12	6

1298	Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep. 2006 , 291, H1216-25	2
1297	Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate alpha-ENaC and sgk1 expression in renal collecting duct epithelia. 2006 , 290, F306-12	27
1296	Controversies regarding hormone therapy: Insights from inflammation and hemostasis. 2006 , 70, 22-30	27
1295	Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial. 2006 , 1, e26	2
1294	Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. 2006 , 154, 101-7	16
1293	Vitamin D status and cancer incidence and mortality: something new under the sun. 2006 , 98, 428-30	19
1292	Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. 2006 , 48, 246-53	96
1291	Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. 2006 , 47, 349-55	21
1290	FIVE AUTHORS REPLY. 2006 , 163, 1068-1069	4
1289	Hormone replacement therapy and acute myocardial infarction: a large observational study exploring the influence of age. 2006 , 35, 731-8	12
1288	Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. 2006 , 295, 655-66	738
1287	The proof for prevention: beyond observations. 2006 , 166, 486	
1286	Polycystic ovary syndrome and the postmenopausal woman. 2006 , 12, 143-8	5
1285	Rethinking primary prevention of atherosclerosis-related diseases. 2006 , 114, 2517-27	80
1284	Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. 2006 , 166, 357-65	439
1283	Hormones and cardiovascular health in women. 2006 , 12, 483-97	72
1282	C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention. 2006 , 237-260	
1281	Estrogen and heart disease: alternatives to a paradigm in crisis. 2006 , 166, 2160	

1280	Estrogen and Heart Disease: Alternatives to a Paradigm in CrisisReply. 2006 , 166, 2160	
1279	Commentary: hormones, heart disease, and the definition of hormone 'initiation'. 2006 , 35, 738-9; discussion 740	3
1278	Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies. 2006 , 9, 416-20	10
1277	Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. 2006 , 15, 35-44	314
1276	Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. 2006 , 9, 146-51	9
1275	Re: "combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the women's health initiative clinical trial". 2006 , 163, 1067-8; author reply 1068-9	12
1274	Acute myocardial infarction in pregnancy: a United States population-based study. 2006 , 113, 1564-71	364
1273	The latest elaboration of the Women's Health Initiative data on hormone replacement therapy and cardiovascular disease in postmenopausal women. 2007 , 23, 183-5	4
1272	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed	927
1271	Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. 2007 , 27, 1782-7	71
1270	Physical activity and risk of hot flashes among women in midlife. 2007 , 16, 124-33	41
1269	Effect of sex hormones on renal estrogen and angiotensin type 1 receptors in female and male rats. 2007 , 292, R794-9	76
1268	The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women. 2007 , 10, 400-7	7
1267	Estrogen-TNF interactions and vascular inflammation. 2007 , 292, H2566-9	11
1266	Number of women needed in a prospective trial to prove potential cardiovascular benefit of hormone replacement therapy. 2007 , 10, 238-43	8
1265	High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. 2007 , 67, 257-63	13
1264	Discoordinate regulation of renal nitric oxide synthase isoforms in ovariectomized mRen2. Lewis rats. 2007 , 292, R819-26	25
1263	Preclinical and clinical properties of trimegestone: a potent and selective progestin. 2007 , 23, 310-9	8

1262	Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells. 2007 , 23, 131-7	24
1261	Epidemiology and Risk Factors of Cardiovascular Disease in Postmenopausal Women. 2007 , 405-452	5
1260	Gender and Cardiovascular Disease. 2007 , 555-575	
1259	Sex and the cardiovascular system: the intriguing tale of how women and men regulate cardiovascular function differently. 2007 , 31, 17-22	100
1258	Recent epidemiological evidence relevant to the clinical management of the menopause. 2007 , 10 Suppl 2, 2-15	22
1257	Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited. 2007 , 10, 195-6	11
1256	Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. 2007 , 28, 2028-40	107
1255	Drospirenone increases endothelial nitric oxide synthesis via a combined action on progesterone and mineralocorticoid receptors. 2007 , 22, 2325-34	42
1254	Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?. 2007 , 22, 2738-42	20
1253	Managing the menopause. 2007 , 334, 736-41	29
1252	[Recommendations for estrogen and progesterone substitution in climacteric and postmenopause]. 2007 , 47, 45-8	
1251	Major and minor ECG abnormalities in asymptomatic women and risk of cardiovascular events and mortality. 2007 , 297, 978-85	91
1250	HRT and the young at heart. <i>New England Journal of Medicine</i> , 2007 , 356, 2639-41	59.2 95
1249	Pathogenesis of atherosclerosis: is obstructive sleep apnea the new kid on the block?. 2007 , 176, 634-5	2
1248	Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. 2007 , 148, 538-47	66
1247	Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. 2007 , 335, 239	157
1246	[Treatment of osteoporosis]. 2007 , 58, 55-71	
1245	The metabolic syndrome in women. 2007 , 3, 696-704	65

1244	Women's willingness to accept perceived risks for vasomotor symptom relief. 2007 , 16, 1028-40	21
1243	Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. 2007 , 297, 1465-77	1151
1242	Physiological Basis of Aging and Geriatrics. 2007 ,	22
1241	An Introduction to Biostatistics: Randomization, Hypothesis Testing, and Sample Size Estimation. 2007 , 165-196	3
1240	Hormones and heart disease in women: the timing hypothesis. 2007 , 166, 506-10	68
1239	Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. 2007 , 92, 3068-75	140
1238	Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?. 2007 , 166, 511-7	55
1237	Changes in adiponectin and inflammatory genes in response to hormonal imbalances in female mice and exacerbation of depot selective visceral adiposity by high-fat diet: implications for insulin resistance. 2007 , 148, 5667-79	12
1236	Drospirenone and its antialdosterone properties. 2007 , 10 Suppl 1, 11-8	67
1235	Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. 2007 , 13, 124-31	8
1234	testing theories with qualitative and quantitative predictions. 2007 , 6, 124-133	13
1233	Oral administration of 17beta-estradiol over 3 months without progestin co-administration does not improve coronary flow reserve in post-menopausal women: a randomized placebo-controlled cross-over CMR study. 2007 , 9, 665-72	6
1232	Women's needs for CAM information to manage menopausal symptoms. 2007 , 10, 215-24	10
1231	Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists. 2007 , 10, 508-26	47
1230	Abdominal aortic aneurysm: the prognosis in women is worse than in men. 2007 , 115, 2865-9	139
1229	Re: "invited commentary: Hormone therapy and risk of coronary heart disease-why renew the focus on the early years of menopause?". 2007 , 166, 1480-1; author reply 1481-2	0
1228	Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. 2007 , 10 Suppl 1, 32-41	18
1227	Postmenopausal hormones and coronary artery disease: potential benefits and risks. 2007 , 10 Suppl 2, 21-6	12

1226	Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. 2007 , 115, 1481-501	533
1225	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. 2007 , 2, 898-905	117
1224	The effect of community nurses and health volunteers on child mortality: the Navrongo Community Health and Family Planning Project. 2007 , 35, 599-608	35
1223	Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. 2007 , 2, 197-210	1
1222	Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. 2007 , 109, 1862-9	45
1221	Hormone Replacement Therapy and Cardiovascular Disease. 273-285	
1220	Parenteral versus oral treatment of postmenopausal women with estrogen. 2007 , 14, 968-70	3
1219	Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. 2007 , 22, 434-42	7
1218	High-frequency oscillation: how high should we go?. 2007 , 35, 1623-4	4
1217	Drospirenone, a progestin with added value for hypertensive postmenopausal women. 2007 , 14, 352-4	3
1216	High-frequency oscillation in acute respiratory distress syndrome: who rescues the rescuer?. 2007 , 35, 1619-20	1
1215	Anemic heart: best kept under pressure?. 2007 , 35, 1615-7	1
1214	Transfer surcharge. 2007 , 35, 1612-3	
1213	Properties of 2 counterfactual effect definitions of a point exposure. 2007 , 18, 453-60	44
1212	Effects of dietary equol on body weight gain, intra-abdominal fat accumulation, plasma lipids, and glucose tolerance in ovariectomized Sprague-Dawley rats. 2007 , 14, 925-32	49
1211	Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study. 2007 , 14, 624-9	54
1210	Postmenopausal hormone therapy in clinical perspective. 2007 , 14, 944-57	37
1209	Critical care services and trial methodology: even at the turning of the tide. 2007 , 35, 1620-2	3

1208	It is time to pay attention--now more than ever!. 2007 , 35, 1629-30	5
1207	Systemic inflammation and sexual dimorphism: more than meets the eye. 2007 , 35, 1610-2	6
1206	Prerenal azotemia: still a useful concept?. 2007 , 35, 1630-1	15
1205	Antibiotic therapy for community-acquired pneumonia with septic shock: follow the guidelines. 2007 , 35, 1617-8	5
1204	Golden hours wasted: the human cost of intensive care unit and emergency department inefficiency. 2007 , 35, 1614-5	7
1203	Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. 2007 , 14, 251-60	44
1202	Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. 2007 , 14, 235-42	4
1201	Sex hormone ratio changes in men and postmenopausal women with coronary artery disease. 2007 , 14, 385-90	30
1200	Update on the cardiovascular risks of hormone replacement therapy. 2007 , 3, 87-97	9
1199	Testosterone and cardiovascular disease in men. 2007 , 3, 375-381	
1198	Angeliq for Treatment of Menopausal Symptoms. 2007 , 110, 177-178	
1197	Recombinant human activated protein C sentenced to the death of a thousand cuts?. 2007 , 35, 1609-10	2
1196	Optimizing the treatment of a new horseman of the Apocalypse. 2007 , 35, 1626-7	1
1195	The relationship between physical activity and lipoprotein subclasses in postmenopausal women: the influence of hormone therapy. 2007 , 14, 115-22	8
1194	Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. 2007 , 14, 373-84	125
1193	Endotracheal tube cuff leak: can optimum management of cuff pressure prevent pneumonia?. 2007 , 35, 1624-6	6
1192	Acidosis and impaired blood coagulation: what and how to correct before using recombinant human factor VIIa. 2007 , 35, 1627-9	6
1191	Historical Perspectives in Postmenopausal Hormone Therapy: Defining the Right Dose and Duration. 2007 , 82, 219-226	3

1190	Menopause. 2007 , 2, 1-20	6
1189	Pharmacological postconditioning with the phytoestrogen genistein. 2007 , 42, 79-87	75
1188	Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?. 2007 , 153, 182-8	25
1187	Menstrual and reproductive factors and risk of non-fatal acute myocardial infarction in Italy. 2007 , 134, 67-72	32
1186	Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. 2007 , 1772, 72-80	128
1185	Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women. 2007 , 87, 849-57	11
1184	Estrogen increases apoptosis in the arterial wall in a murine atherosclerosis model. 2007 , 88, 1190-6	14
1183	Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms. 2007 , 380, 157-64	29
1182	Observation versus intervention in the evaluation of drugs: the story of hormone replacement therapy. 2007 , 330, 347-55	2
1181	[Hormone replacement therapy in postmenopausal women: all the treatments are not the same]. 2007 , 35, 388-97	6
1180	Benefits and risks of long-term low-dose oral continuous combined hormone therapy. 2007 , 56, 231-48	26
1179	The effects of black cohosh therapies on lipids, fibrinogen, glucose and insulin. 2007 , 57, 195-204	26
1178	Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease. 2007 , 57, 239-46	14
1177	WHI risks: any relevance to menopause management?. 2007 , 57, 6-10	7
1176	HRT and the primary prevention of cardiovascular disease. 2007 , 57, 31-4	21
1175	Endometrial bleeding during hormone therapy: the effect of progestogens. 2007 , 57, 71-6	9
1174	A simulation using data from a primary care practice database closely replicated the women's health initiative trial. 2007 , 60, 686-95	42
1173	How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. 2007 , 60, 1205-19	143

1172	Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia. 2007 , 116, 34-9	8
1171	Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study. 2007 , 195, 181-8	21
1170	Traitement m̃dicamenteux du diab̃te de type 2recommandation de bonne pratique. 2007 , 33, S26-S105	5
1169	Bioidentical hormone therapy: a review of the evidence. 2007 , 16, 600-31	53
1168	Rosuvastatin in elderly patients. 2007 , 24, 933-44	6
1167	Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. 2007 , 24, 361-79	81
1166	Calcium/vitamin D supplementation and cardiovascular events. 2007 , 115, 846-54	536
1165	Variations on hormone replacement therapy: an answer to the 'one dose fits all' Women's Health Initiative study. 2007 , 23, 665-71	10
1164	Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. 2007 , 4, 89-102	59
1163	Ubiquinol-cytochrome-c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension. 2007 , 85, 986-96	4
1162	Timing is everything. 2007 , 23, 1-4	11
1161	Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. 2007 , 23, 692-9	14
1160	Menopause: developing a rational treatment plan. 2007 , 23, 682-91	3
1159	Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels. 2007 , 23 Suppl 1, 9-16	6
1158	Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. 2007 , 23, 436-44	5
1157	Hormone replacement as the first-line prevention for postmenopausal osteoporosis. 2007 , 2, 689-700	1
1156	Reducing the risk of cardiovascular disease in older women. 2007 , 49, 32-35	
1155	Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator--a hybrid structure of 17beta-estradiol and vitamin E in hippocampal neurons. 2007 , 50, 4471-81	37

1154	Hormonal replacement therapy (HRT) in postmenopause: a reappraisal. 2007 , 68, 241-50	13
1153	Sleep Apnea and Neuroendocrine Function. 2007 , 2, 225-236	10
1152	Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration. 2007 , 82, 219-26	7
1151	[Postmenopausal hormone therapy and vascular risk]. 2007 , 163, 851-6	0
1150	Traitement hormonal substitutif de la ménopause et diabète. 2007 , 1, 19-27	2
1149	[Therapeutics issues in osteoporosis]. 2007 , 129, 773-4	1
1148	Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?. 2007 , 67, 647-55	11
1147	New perspectives on Mars and Venus: unravelling the role of androgens in gender differences in cardiovascular biology and disease. 2007 , 16, 185-92	26
1146	ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular	1412
1145	Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. 2007 , 49, 1230-50	192
1144	Role of Sex Steroids in Hypertension. 2007 , 397-403	
1143	Primary Prevention of Ischemic Heart Disease. 2007 , 178-220	1
1142	Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. 2007 , 167, 905-12	93
1141	A critique of Women's Health Initiative Studies (2002-2006). 2006 , 4, e023	19
1140	Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. 2007 , 125-146	
1139	Non ST-Elevation Acute Coronary Syndromes. 2007 , 221-245	
1138	Randomized Controlled Trials and the Effects of Postmenopausal Hormone Therapy on Cardiovascular Disease: Facts, Hypotheses, and Clinical Perspective. 2007 , 529-564	
1137	GUIDELINES ON THE MANAGEMENT OF STABLE ANGINA PECTORIS (ENDING). 2007 , 3, 69-100	

1136	A tale of two studies: the importance of setting, subjects and context in two randomized, controlled trials of a web-based decision support for perimenopausal and postmenopausal health decisions. 2007 , 66, 211-22	26
1135	Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media. 2007 , 16, 28-31	11
1134	Endocrine regulation of ageing. 2007 , 8, 681-91	275
1133	Oestrogen receptor alpha gene expression levels are reduced in obese compared to normal weight females. 2007 , 31, 900-7	65
1132	Trust in scientific experts on obesity: implications for awareness and behavior change. 2007 , 15, 2145-56	34
1131	17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. 2007 , 34, 972-8	12
1130	Non-genomic vascular actions of female sex hormones: physiological implications and signalling pathways. 2007 , 34, 822-6	20
1129	Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. 2007 , 66, 27-34	20
1128	Hypotheses, tests, methods, and innovation: the balancing act in research. 2007 , 48, 2204-16	1
1127	Sleep complaints in community-living older persons: a multifactorial geriatric syndrome. 2007 , 55, 1853-66	144
1126	Care of the menopausal patient: a nurse practitioner's view. 2007 , 19, 427-37	6
1125	Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis. 2007 , 16 Suppl 3, S1-9	10
1124	Factors affecting the risk of hip fractures. 2007 , 38, 735-44	52
1123	HDL cholesterol: physiology, pathophysiology, and management. 2007 , 32, 268-314	56
1122	Regulatory considerations in the development of high-density lipoprotein therapies. 2007 , 100, n10-4	5
1121	Combination therapy for treatment of osteoporosis: A review. 2007 , 197, 559-65	21
1120	The role of gender differences in beta-adrenergic receptor responsiveness of diabetic rat heart. 2007 , 305, 63-9	15
1119	Kardiovaskuläre Risiken unter HRT in der Postmenopause. 2007 , 5, 120-126	4

1118	Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects. 2007 , 275, 335-9	3
1117	The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. 2007 , 5, 153-9	22
1116	Postmenopausal hormone therapy and cardiovascular disease: Making sense of the evidence. 2007 , 1, 138-147	5
1115	Hormontherapie in den Wechseljahren. 2008 , 41, 858-864	
1114	Kardiovaskuläres Risiko in der Postmenopause und Hormonersatztherapie. 2008 , 41, 879-883	
1113	Self-Experimentation and Web Trials. 2008 , 21, 7-9	
1112	[Secondary prevention after myocardial infarction]. 2008 , 49, 1052-60	0
1111	Geschlechtsspezifische Aspekte beim metabolischen Syndrom. 2008 , 4, 182-188	
1110	Modulation of the genomic estrogen receptor pathway by water extracts of <i>Cirsium japonicum</i> . 2008 , 31, 225-30	7
1109	Hormonersatztherapie und kardiovaskuläre Erkrankungen. 2008 , 2, 435-448	
1108	[Cohort studies]. 2008 , 158, 174-9	0
1107	Hyperviscosity syndrome in ovariectomized rats. 2008 , 146, 92-5	2
1106	Advances in hormone replacement therapy: making the menopause manageable. 2008 , 8, 22	35
1105	Study Protocol: effects of acupuncture on hot flushes in perimenopausal and postmenopausal women - a multicenter randomized clinical trial. 2008 , 9, 70	4
1104	The medical management of menopause: to treat or not to treat?. 2008 , 1127, 134-9	6
1103	Hormone therapy, dilemmas, medical decisions. 2008 , 36, 73-88, 4	3
1102	Assessing intrauterine influences on offspring health outcomes: can epidemiological studies yield robust findings?. 2008 , 102, 245-56	203
1101	Cholesterol--when is lower better?. 2008 , 83, 777-80	6

- 1100 Postmenopausal hormone use: what does the latest evidence show?. **2008**, 12, 56-61
- 1099 Possible risk factor for postmenopausal women: postprandial hypertriglyceridemia. **2008**, 34, 1032-6 1
- 1098 Experiences of a long-term randomized controlled prevention trial in a maiden environment: Estonian Postmenopausal Hormone Therapy trial. **2008**, 8, 51
- 1097 Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials). **2008**, 102, 693-9 41
- 1096 Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. **2008**, 101, 1599-1605 49
- 1095 Baja masa ñea y factores ginecol3gicos asociados en mujeres climat3ficas. **2008**, 17, 35-43
- 1094 ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. **2008**, 23, 53-56
- 1093 Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. **2008**, 57, 1088-92 39
- 1092 Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update. **2008**, 68, 339-58 4
- 1091 [Usefulness of phyto-oestrogens in reduction of blood pressure. Systematic review and meta-analysis]. **2008**, 40, 177-86 7
- 1090 Funci3n endotelial en la arteria que causa el infarto: ¿es importante la modalidad del tratamiento de reperfusi3n?. **2008**, 61, 797-799 1
- 1089 Gender and Cardiovascular Diseases in Aging. **2008**, 307-338
- 1088 Endothelial Function in Infarct-Related Arteries: Does the Type of Reperfusion Therapy Matter?. **2008**, 61, 797-799
- 1087 Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. **2008**, 52, 124-31 63
- 1086 Cardiovascular risk factors for heart disease and stroke in women by age and time since menopause, in seven Latin American cities: The CARMELA study. **2008**, 3, 181-189 5
- 1085 Treating hot flashes in menopausal women with homeopathic treatment--results of an observational study. **2008**, 97, 10-5 25
- 1084 Epidemiologic Methods in Studies of Osteoporosis. **2008**, 645-666 1
- 1083 Sex steroids and vascular responses in hypertension and aging. **2008**, 5 Suppl A, S46-64 47

1082	Sex-specific differences in ischemic heart failure: role of estrogen. 2008 , 5, 239-43	3
1081	The medical management of menopause: a four-country comparison care in urban areas. 2008 , 59, 7-21	69
1080	Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. 2008 , 59, 249-58	10
1079	Effects of black cohosh extract on body weight gain, intra-abdominal fat accumulation, plasma lipids and glucose tolerance in ovariectomized Sprague-Dawley rats. 2008 , 60, 209-15	40
1078	Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. 2008 , 60, 185-201	76
1077	Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. 2008 , 283, 49-57	144
1076	Can menopausal hormone therapy prevent coronary heart disease?. 2008 , 19, 206-12	11
1075	Haemostatic effects of phytoestrogen genistein in postmenopausal women. 2008 , 123, 231-5	5
1074	17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. 2008 , 14, 245-53	65
1073	Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. 2008 , 90, 642-72	50
1072	Estrogen and progestogen therapy in postmenopausal women. 2008 , 90, S88-102	21
1071	Timing of estrogen replacement influences atherosclerosis progression and plaque leukocyte populations in ApoE ^{-/-} mice. 2008 , 201, 43-52	15
1070	Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertension. 2008 , 2, 20-7	8
1069	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. 2008 , 371, 1417-26	687
1068	Sex and sex steroids in cardiovascular-renal physiology and pathophysiology. 2008 , 5 Suppl A, S1-2	8
1067	Need for research on estrogen receptor function: importance for postmenopausal hormone therapy and atherosclerosis. 2008 , 5 Suppl A, S19-33	24
1066	Update on hormones, menopause, and heart disease: evaluating professional responses to the Women's Health Initiative. 2008 , 29, 720-37	8
1065	Differential mass spectrometry of rat plasma reveals proteins that are responsive to 17beta-estradiol and a selective estrogen receptor modulator PPT. 2008 , 7, 4373-83	10

1064	Oral contraceptives in systemic lupus erythematosus: the case for (and against). 2008 , 17, 708-10	4
1063	Generalizability of the results of randomized trials. 2008 , 168, 133-5	56
1062	Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. 2008 , 299, 1036-45	279
1061	Oral contraceptives, hormone therapy and cardiovascular risk. 2008 , 11, 355-63	12
1060	Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. 2008 , 13, 1224-34	37
1059	Measures for Conducting Comparative Benefit: Risk Assessment. 2008 , 42, 223-233	18
1058	Authors' Response, Part I: Observational Studies Analyzed Like Randomized Experiments. 2008 , 19, 789-792	22
1057	Hormone therapy and risk of myocardial infarction: a national register study. 2008 , 29, 2660-8	85
1056	Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. 2008 , 74, 370-6	47
1055	Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. 2008 , 168, 2245-53	60
1054	[Recommendations for hormone treatment with estrogen and progesterone in the climacteric and postmenopausal periods. 37th Workshop of the Zurich Discussion Group, September 2006]. 2008 , 48, 38-46	0
1053	The women's health initiative: lessons learned. 2008 , 29, 131-50	57
1052	Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents. 2008 , 11, 74-83	14
1051	Menopause and hypertension: an age-old debate. 2008 , 51, 952-9	163
1050	Effects of estrogen therapy on microalbuminuria in healthy post-menopausal women. 2008 , 24, 681-5	9
1049	Re-think HRT: behind the scene of perceptions. 2008 , 11, 443-6	2
1048	Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. 2008 , 118, 1294-303	191
1047	Primary prevention of coronary heart disease in women. 2008 , 14, 40-5	20

1046	Hormones and cardiovascular disease. 2008 , 24, 483-4	2
1045	Coronary heart disease and HRT in France: MISSION study prospective phase results. 2008 , 24, 696-700	2
1044	Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. 2008 , 36, 1218-26	17
1043	Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression. 2008 , 294, H2444-55	37
1042	Effects of menopausal status on circulating calcitonin gene-related peptide and adipokines: implications for insulin resistance and cardiovascular risks. 2008 , 11, 364-72	23
1041	Oestrogen plays a permissive role in cardioprotection. 2008 , 79, 353-4	3
1040	Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. 2008 , 14, 225-34	36
1039	Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. 2008 , 17, 114-23	21
1038	Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. 2008 , 36, 1753-69	16
1037	Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor. 2008 , 197, 447-62	53
1036	Physiological concentration of 17beta-estradiol on sympathetic reinnervation in ovariectomized infarcted rats. 2008 , 149, 1205-13	8
1035	Approach to the patient with menopausal symptoms. 2008 , 93, 4567-75	42
1034	Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials. 2008 , 28, 1666-71	46
1033	Premenopausal oophorectomy and the risk for dementia. 2008 , 4, 127-31	4
1032	Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. 2008 , 168, 861-6	127
1031	Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. 2008 , 93, 2097-103	21
1030	Prevalence and opinions of hormone therapy prior to the Women's Health Initiative: a multinational survey on four continents. 2008 , 17, 1151-66	15
1029	Vitamin D deficiency and risk of cardiovascular disease. 2008 , 117, 503-11	1770

1028	Self-Experimentation and Web Trials. 2008 , 21, 7-9	5
1027	Hormone replacement therapy: risks and benefits. 2008 , 6, 433-439	3
1026	Osteoporosis medication use in nursing home patients with fractures in 1 US state. 2008 , 168, 1111-5	29
1025	Hormone therapy and stroke. 2008 , 51, 581-91	5
1024	Inflammation, coronary artery disease, and hormones. 2008 , 15, 1036-8	3
1023	Menopause does not affect blood pressure and risk profile, and menopausal women do not become similar to men. 2008 , 26, 1983-92	61
1022	Individualizing the risks and benefits of postmenopausal hormone therapy. 2008 , 15, 374-81	10
1021	Symptoms of menopause: hot flushes. 2008 , 51, 539-48	41
1020	Postmenopausal hormone therapy and cardiovascular disease in perspective. 2008 , 51, 564-80	31
1019	Low-dose estradiol gel 0.1% for the treatment of vasomotor symptoms associated with menopause. 2008 , 3, 155-162	
1018	Hormone replacement therapy and stroke. 2008 , 6, 112-23	39
1017	Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. 2008 , 19, 766-79	507
1016	Low-Dose Transdermal Estrogens. 2008 , 111, 209-211	
1015	Post-menopausal hormone therapy and cardiovascular events: a new paradigm based on pharmacogenetics?. 2008 , 4, 19-21	1
1014	Sex hormones and circulating lipoprotein levels. 2008 , 3, 603-606	3
1013	Data analysis methods and the reliability of analytic epidemiologic research. 2008 , 19, 785-8; discussion 789-93	7
1012	Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. 2008 , 15, 248-55	6
1011	Effects of phytoestrogens derived from red clover on atherogenic adhesion molecules in human endothelial cells. 2008 , 15, 542-50	18

1010	Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. 2008 , 15, 1060-4	6
1009	Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. 2008 , 15, 584-602	146
1008	Women's Health Initiative: Statistical Aspects and Selected Early Results. 2008 , 1	
1007	Relaxin as a natural agent for vascular health. 2008 , 4, 515-24	37
1006	Women's Health Initiative Hormone Therapy Trials. 2008 , 1	
1005	Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative. 2008 , 14, 7-13	13
1004	The Pharmacology of Selective Estrogen Receptor Modulators. 2008 , 887-919	
1003	Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?. 2008 , 6, 239-259	14
1002	Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. 2008 , 138, 297-304	97
1001	Explaining risk. 9-16	
1000	Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer. 2008 , 3, 647-57	14
999	Bazedoxifene for the prevention of postmenopausal osteoporosis. 2008 , 4, 1229-42	23
998	The Pharmacology of Estrogens in Osteoporosis. 2008 , 1769-1775	
997	Lasofexifene: Evidence of its therapeutic value in osteoporosis. 2010 , 4, 113-29	8
996	Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol. 2009 , 199-201	1
995	Hormone Therapies and Menopause: Where Do We Stand in the Post-WHI Era?. 2009 , 127-144	
994	Coronary heart disease. 263-282	
993	Diabetes in mid-life women. 283-296	

992	Risk factors for age-related maculopathy. 2009 , 2009, 360764	26
991	[Progestagen use in oral contraception - basic knowledge]. 2009 , 66, 71-87	1
990	Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. 2009 , 338, b219	94
989	Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. 2009 , 12 Suppl 1, 66-70	9
988	An open-label study of subdermal implants of estradiol-only versus subdermal implants of estradiol plus norgestrel acetate: effects on symptom control, lipid profile and tolerability. 2009 , 25, 269-75	2
987	Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. 2009 , 119, 922-30	89
986	Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. 2009 , 170, 24-8	48
985	Type and route of estrogen administration. 2009 , 12 Suppl 1, 86-90	34
984	Breast cancer after use of estrogen plus progestin in postmenopausal women. <i>New England Journal of Medicine</i> , 2009 , 360, 573-87	59.2 345
983	Effects of progesterone and its antagonist mifepristone on progesterone receptor expression in human umbilical vein endothelial cells. 2009 , 67, 269-74	4
982	Postmenopausal hypertension: mechanisms and therapy. 2009 , 54, 11-8	124
981	Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease. 2009 , 37, 969-82	16
980	Salivary sex hormone measurement in a national, population-based study of older adults. 2009 , 64 Suppl 1, i94-105	40
979	Cardiovascular effects of noncardiovascular drugs. 2009 , 120, 1123-32	17
978	Hormone replacement therapy and cardiovascular disease revisited. 2009 , 15, 55-7	17
977	Renal function predicts cardiovascular outcomes in southern Italian postmenopausal women. 2009 , 16, 481-6	12
976	Postmenopausal hormone therapy and the risk of cardiovascular disease. 2009 , 10, 2041-53	4
975	Evidence for a role of hot flashes in vascular function in recently postmenopausal women. 2009 , 113, 902-908	36

974	Long term hormone therapy for perimenopausal and postmenopausal women. 2009 , CD004143	46
973	Lasofoxifene: a new-generation SERM for the treatment of postmenopausal osteoporosis. 2009 , 4, 607-617	
972	Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. 2009 , 35, 295-306	40
971	Ospemifene use in postmenopausal women. 2009 , 18, 839-49	26
970	Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. 2009 , 179, 835-42	170
969	Rapid estrogen receptor-alpha activation improves ischemic tolerance in aged female rats through a novel protein kinase C epsilon-dependent mechanism. 2009 , 150, 889-96	46
968	The potential for estrogens in preventing Alzheimer's disease and vascular dementia. 2009 , 2, 31-49	52
967	Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. 2009 , 10, 2209-20	27
966	Aspirin therapy in women: back to the ABCs. 2009 , 2, 63-4	5
965	Vascular effects of estrogen and progestins and risk of coronary artery disease: importance of timing of estrogen treatment. 2009 , 60, 308-17	9
964	Cancer prevention: from 1727 to milestones of the past 100 years. 2009 , 69, 5269-84	94
963	Efficacy, safety, and tolerability of low-dose hormone therapy in managing menopausal symptoms. 2009 , 22, 563-73	15
962	Prevention, screening, and management of osteoporosis: an overview of the current strategies. 2009 , 121, 5-17	36
961	Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. 2009 , 170, 12-23	165
960	Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study. 2009 , 2, 78-87	15
959	Age- and gender-specific changes in the left ventricular relaxation: a Doppler echocardiographic study in healthy individuals. 2009 , 2, 41-6	103
958	Estrogen decreases atherosclerosis in part by reducing hepatic acyl-CoA:cholesterol acyltransferase 2 (ACAT2) in monkeys. 2009 , 29, 1471-7	32
957	Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats. 2009 , 200, 75-84	24

956	Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. 2009 , 15, 341-58	26
955	Effect of cardiorespiratory fitness on vascular regulation and oxidative stress in postmenopausal women. 2009 , 54, 1014-20	69
954	Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. 2009 , 169, 784-5; author reply 785-6	7
953	Optimism, cynical hostility, and incident coronary heart disease and mortality in the Women's Health Initiative. 2009 , 120, 656-62	307
952	Preventing and Treating Osteoporosis: Pharmacologic and Nonpharmacologic Approaches. 2009 , 5, S13-S20	2
951	Vitamin D and cardiovascular disease. 2009 , 29, 691-708	82
950	Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. 2009 , 29, 775-83	10
949	Menopause and menopause transition. Preface and introduction. 2009 , 23, 1-6	2
948	HRT and cardiovascular disease. 2009 , 23, 109-20	27
947	[Dyslipidemia in women after 50: age, menopause or both?]. 2009 , 58, 159-64	5
946	The Women's Health Initiative Randomized Controlled Dietary Modification Trial: a post-mortem. 2009 , 114, 1-6	24
945	Bone health in systemic lupus erythematosus. 2009 , 11, 177-84	26
944	Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). 2009 , 2, 228-39	110
943	Estrogen-eluting stents. 2009 , 2, 240-4	9
942	Influence of maternal dysmetabolic conditions during pregnancy on cardiovascular disease. 2009 , 2, 277-85	43
941	Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. 2009 , 57, 1810-5	25
940	Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. 2009 , 158, 1951-60	8
939	Cholesterol goals: moving from numbers to treatment. 2009 , 32, 106-8	

938	Osteoporosis and Strength Training. 2009 , 3, 310-319	6
937	Effects of hormonal treatment on lipids in patients with cancer. 2009 , 35, 175-84	41
936	Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. 2009 , 142, 139-44	13
935	Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. 2009 , 147, 195-200	9
934	Retinal vascular caliber: systemic, environmental, and genetic associations. 2009 , 54, 74-95	296
933	Preventive cardiology and cardiac rehabilitation programmes in women. 2009 , 63, 28-33	12
932	Use of dydrogesterone in hormone replacement therapy. 2009 , 65 Suppl 1, S51-60	10
931	Cognitive benefits of hormone therapy: cardiovascular factors and healthy-user bias. 2009 , 64, 182-7	10
930	Endocrine function in naturally long-living small mammals. 2009 , 299, 101-11	52
929	Clinical trial design and evidence-based outcomes in the study of liver diseases. 2009 , 50, 817-26	10
928	The normalization heuristic: an untested hypothesis that may misguide medical decisions. 2009 , 72, 745-8	8
927	The cost-effectiveness of hormone therapy in younger and older postmenopausal women. 2009 , 122, 42-52.e2	55
926	Contraceptive hormone use and cardiovascular disease. 2009 , 53, 221-31	186
925	Lipid profile and inflammatory markers associated with estrogen receptor alpha PvuII and XbaI gene polymorphisms. 2009 , 153, 288-95	6
924	Hormone Replacement Therapy [The Silver Bullet That Misfired]. 2009 , 155-171	
923	Epidemiology and Biostatistics. 2009 ,	18
922	Postmenopausal estrogen and progestin effects on the serum proteome. 2009 , 1, 121	29
921	Using a global proteomic approach to identify proteins affected by estrogen therapy. 2009 , 1, 58	0

920	Coronary heart disease and hormone replacement therapy after the menopause. 2009 , 12 Suppl 1, 71-5	20
919	Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. 2009 , 12, 206-9	16
918	Estrogen and mechanisms of vascular protection. 2009 , 29, 289-95	237
917	Estrogen actions in the cardiovascular system. 2009 , 12 Suppl 1, 18-21	35
916	Psychosocial work environment and lifestyle as related to lipid profiles in perimenopausal women. 2009 , 12, 131-45	12
915	Is HRT still indicated for the primary prevention of osteoporosis?. 2009 , 25, 629-33	1
914	The influence of smoking on bone loss and response to nasal estradiol. 2009 , 12, 59-65	12
913	The role of estrogen receptor subtypes for vascular maintenance. 2009 , 25, 82-95	19
912	Coronary heart disease and menopause management: the swinging pendulum of HRT. 2009 , 207, 336-40	46
911	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. 2009 , 374, 1243-51	219
910	Another nail in the coffin for hormone-replacement therapy?. 2009 , 374, 1217-8	8
909	Depressione e climaterio. 2009 , 28, 34-43	
908	Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. 2009 , 6 Suppl 1, 37-59	15
907	Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. 2009 , 16, 1156-66	130
906	Lipoprotein a: where are we now?. 2009 , 24, 351-7	44
905	Getting to the heart of the matter: asymmetric dimethylarginine and menopause. 2009 , 16, 8-10	
904	Menopausal hot flashes: how long do they really last?. 2009 , 16, 427	2
903	Effect of hot flashes on vascular function: a randomized controlled trial. 2009 , 114, 777-785	28

902 Cardiovascular Disease. **2009**, 31, S11-S18

901 Hormone therapy: rigour and responsibility in knowledge translation. **2009**, 31, 13-5, 16-9 1

900 The role of statins for the primary and secondary prevention of coronary heart disease in women. **2009**, 15, 1054-62 17

899 Delivery may affect arterial elasticity in women. **2009**, 73, 750-4 11

898 Hormonothérapie : Rigueur et responsabilité en matière d'application des connaissances. **2009**, 31, 16-19

897 Progestone et progestatifs de synthèse. **2009**, 4, 1-21

896 Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease. **2009**, 5, 283-306 14

895 Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women. **2009**, 16, 407-12 7

894 Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. **2009**, 16, 559-65 10

893 Systemic effects of vaginally administered estrogen therapy: a review. **2010**, 16, 188-95 16

892 The hazards of hazard ratios. **2010**, 21, 13-5 551

891 Prothrombotic effects of contraceptives. **2010**, 16, 3490-6 11

890 Ménopause. **2010**, 7, 1-19 1

889 Retinal microvascular structure: determinants and potential utility of novel imaging measurements. **2010**, 5, 353-363 2

888 Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. **2010**, 17, 303-8 9

887 Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. **2010**, 17, 25-54; quiz 55-6 318

886 Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women--a multicenter randomized clinical trial. **2010**, 17, 269-80 70

885 Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease. **2010**, 18, 240-50 10

- 884 Hot flashes and hormone use: harbingers of heart disease?. **2010**, 17, 223-5 2
- 883 Cardiovascular epidemiology of postinfarction angina and menopause age. **2010**, 17, 896-7
- 882 Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. **2010**, 17, 57-63 36
- 881 Biochemical markers for cardiovascular disease in recently postmenopausal women with or without hot flashes. **2010**, 17, 145-51 28
- 880 Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. **2010**, 152, 211-7 78
- 879 Animal, vegetable, or ... clinical trial?. **2010**, 153, 337-9 2
- 878 Gender determinants of cardiovascular risk factors and diseases. **2010**, 11, 207-20 66
- 877 Risikokommunikation. **2010**, 43, 276-281
- 876 Stellenwert der Hormontherapie (HT) zum Erhalt der Knochengesundheit postmenopausaler Frauen. **2010**, 43, 294-300
- 875 Herz-Kreislauf-Risiko und Hormontherapie in der Postmenopause. **2010**, 43, 301-307 1
- 874 Hormontherapie (HT) in der Peri- und Postmenopause. **2010**, 43, 839-847 1
- 873 Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. **2010**, 30, 442-52 9
- 872 17beta-Estradiol decreases vulnerability to ventricular arrhythmias by preserving connexin43 protein in infarcted rats. **2010**, 629, 73-81 24
- 871 Inhibitory signaling of 17 β -estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation. **2010**, 649, 140-9 16
- 870 Menstrual cycle-related exacerbation of disease. **2010**, 202, 221-31 57
- 869 Reduced estrogen in menopause may predispose women to takotsubo cardiomyopathy. **2010**, 7, 71-7 50
- 868 Periodontal disease-associated micro-organisms in peri-menopausal and post-menopausal women using or not using hormone replacement therapy. A two-year follow-up study. **2010**, 10, 10 21
- 867 Sex differences in the coronary vasodilation induced by 17 β -oestradiol in the isolated perfused heart from spontaneously hypertensive rats. **2010**, 200, 203-10 26

866	A mild favorable effect of soy protein with isoflavones on body composition--a 6-month double-blind randomized placebo-controlled trial among Chinese postmenopausal women. 2010 , 34, 309-18	24
865	. 2010 ,	16
864	Hormone therapy and asymmetrical dimethylarginine in postmenopausal women. 2010 , 9, 127-35	3
863	Bibliography. 2010 , 321-339	
862	Antiaging Medicine. 2010 , 145-149	0
861	[Correlation between subjective and objective measurement of climacteric women's hot flashes]. 2010 , 40, 765-74	2
860	Impact of race and gender on antithrombotic therapy. 2010 , 104, 471-84	55
859	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. 2010 , 5, 19-29	34
858	Gender-Specific Aspects of Selected Coronary Heart Disease Risk Factors. 2010 , 162-174	5
857	Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause. 2010 , 15, 69-70	3
856	Is postmenopausal HRT a risk factor for adult-onset asthma?. 2010 , 65, 282-4	6
855	Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics. 2010 , 39, 451-8	31
854	Natural hormone therapy for menopause. 2010 , 26, 81-5	10
853	Menopause management: a cardiovascular risk-based approach. 2010 , 13, 328-39	8
852	A review of transdermal nonpatch estrogen therapy for the management of menopausal symptoms. 2010 , 19, 47-55	11
851	Gynecologic Disorders in the Elderly. 2010 , 716-725	1
850	The soy isoflavones for reducing bone loss (SIRBL) study: a 3-y randomized controlled trial in postmenopausal women. 2010 , 91, 218-30	125
849	Genistein induces estrogen-like effects in ovariectomized rats but fails to increase cardiac GLUT4 and oxidative stress. 2010 , 13, 1369-75	13

848	Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review. 2010 , 16, 23-32	7
847	New insights into sexual dimorphism during progression of heart failure and rhythm disorders. 2010 , 151, 1837-45	14
846	Outcomes research: methods and implications. 2010 , 31, 3-12	5
845	Where do we currently stand with advice on hormone replacement therapy for women?. 2010 , 6, 21-5	5
844	Reevaluating erythropoiesis-stimulating agents. <i>New England Journal of Medicine</i> , 2010 , 362, 1742; author reply 1743-4	59.2 4
843	Emerging facade of menopausal hormone therapy. 2010 , 28, 351-9	2
842	Hormontherapie in der Peri- und Postmenopause [Kurzversion der S3-Leitlinie. 2010 , 70, R64-R82	
841	Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients. 2010 , 5, 245-254	2
840	Review. 2010 , 117, 844	2
839	Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. 2010 , 55, 2080-91	92
838	The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. 2010 , 56, 1113-32	1634
837	The role of hormone therapy in the treatment of osteoporosis. 2010 , 15, 49-51	
836	Hypertension in women: the role of progesterone and aldosterone. 2010 , 13, 307-13	31
835	Gender differences in risk factors for coronary heart disease. 2010 , 65, 149-60	73
834	Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17 β -oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. 2010 , 67, 227-32	33
833	Effect of genistein therapy on plasma levels of asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. 2010 , 94, 764-6	9
832	Cardiovascular diseases in American women. 2010 , 20, 386-93	28
831	Postmenopausal hormone therapy and cardiovascular disease in women. 2010 , 20, 451-8	14

830	Sex and gender differences in cardiovascular-renal physiology and pathophysiology. 2010 , 75, 745-6	29
829	Emerging role of estrogen in the control of cardiometabolic disease. 2010 , 31, 183-9	45
828	[Activity of vestibular organs in menopausal women non-users hormone replacement therapy (HRT)]. 2010 , 64, 10-4	1
827	A cognitive model of menopausal hot flushes and night sweats. 2010 , 69, 491-501	91
826	Amenorrhea. 2010 ,	1
825	Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. 2010 , 2, 48	52
824	Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. 2010 , 27, 533-44	30
823	On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause. 2010 , 13, 303-6	5
822	Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy. 2010 , 42, 334-43	13
821	Climacteric commentaries. 2010 , 13, 395-402	
820	Vasomotor hot flushes and 24-hour ambulatory blood pressure in recently post-menopausal women. 2010 , 42, 216-22	16
819	Burden of illness of hypertension among women using menopausal hormone therapy: a US perspective. 2010 , 26, 2823-32	7
818	Modeling hot flushes and quality of life in breast cancer survivors. 2011 , 14, 171-80	39
817	Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women: implications for hormone replacement therapy. 2011 , 14, 25-30	3
816	Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. 2011 , 14, 369-77	16
815	Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011 , 40, 419-32, ix	5.5 42
814	2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Equipoise and the dilemma of randomized clinical trials. <i>New England Journal of Medicine</i> , 2011 , e215-367	338
813	364, 476-80	59.2 128

812	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	
811	'PROFOX'--the post HRT nightmare. 2011 , 14, 217-9	6
810	Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. 2011 , 124, 199-205	79
809	Cardiac toxicity in breast cancer patients: from a fractional point of view to a global assessment. 2011 , 37, 321-30	60
808	Disruption of CD38 gene enhances cardiac functions by elevating serum testosterone in the male null mice. 2011 , 89, 491-7	11
807	EMAS position statement: Managing the menopause in the context of coronary heart disease. 2011 , 68, 94-7	39
806	A systematic review of menopausal symptom management decision aid trials. 2011 , 69, 11-21	14
805	Endothelial biology in the post-menopausal obese woman. 2011 , 69, 120-5	13
804	Factors related to menopausal symptom management decisions. 2011 , 70, 10-5	12
803	[ESC/EAS Guidelines for the management of dyslipidaemias]. 2011 , 64, 1168.e1-1168.e60	37
802	Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. 2011 , 7, 475-85	11
801	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 32, 1769-818	2020
800	ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217 Suppl 1, S1-44	152
799	ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). 2011 , 217, 3-46	459
798	Metabolic Syndrome Emerging from Menopause. 2011 , 17, 127	11
797	Effect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female rats. 2011 , 44, 786-92	12
796	High-Sensitivity C-Reactive Protein and Cardiovascular Disease. 2011 , 3, 178-186	
795	Osteoporosis prevention. 2011 , 23, 203-10	13

794	Preventing osteoporosis in symptomatic postmenopausal women. 2011 , 18, 109-18	23
793	Age, hormone therapy use, coronary heart disease, and mortality. 2011 , 18, 243-5	2
792	Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. 2011 , 18, 1060-6	38
791	Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor- β genotypes. 2011 , 18, 1101-12	19
790	Distinct cardioprotective effects of 17 β -estradiol and dehydroepiandrosterone on pressure overload-induced hypertrophy in ovariectomized female rats. 2011 , 18, 1317-26	29
789	Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system. 2011 , 29, 273-81	24
788	How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women. 2011 , 7, 433-51	9
787	Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. 2011 , 57, 598-603	84
786	Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. 2011 , 18, 253-61	21
785	Atherosclerosis, hormone therapy, and outcomes in younger postmenopausal women: waiting for more answers. 2011 , 18, 935-6	
784	Delivery of therapeutic agents to the target tissue. 2011 , 18, 1040-1	
783	Gender specific aspects of cell death in the cardiovascular system. 2011 , 17, 1046-55	14
782	Estrogen, hormonal replacement therapy and cardiovascular disease. 2011 , 20, 133-8	179
781	Science at the Crossroads: Fact or Fiction?. 2011 , 30, 79-92	6
780	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause. 2011 , 17 Suppl 6, 1-25	37
779	Vasomotor menopausal symptoms and risk of coronary heart disease: a life course perspective. 2011 , 18, 127-8	
778	Women's risk factors and screening for coronary heart disease. 2011 , 40, 337-46; quiz 346-7	6
777	Disparities in women's cardiovascular health. 2011 , 40, 362-71	7

776	Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists. 2011 , 2, 14	31
775	Factors associated with presence and extent of coronary calcium in those predicted to be at low risk according to Framingham risk score (from the Multi-Ethnic Study of Atherosclerosis). 2011 , 107, 879-85	7
774	Enhanced expression of plasminogen activator inhibitor may prevent cardiac rupture in female and castrated mice after myocardial infarction. 2011 , 8, 239-51	5
773	Increased estrogen receptor α in adipose tissue is associated with increased intracellular and reduced circulating adiponectin protein levels in aged female rats. 2011 , 8, 325-33	24
772	Efectos del estradiol-drospirenona o estradiol-trimegestona sobre los lípidos y lipoproteínas en menopáusicas. 2011 , 38, 50-55	
771	A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. 2011 , 1379, 244-52	56
770	Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?. 2011 , 5, 280-286	
769	Update in HIV medicine for the generalist. 2011 , 26, 538-42	1
768	Complementary and alternative medicine in the treatment of menopausal symptoms. 2011 , 17, 883-8	13
767	Phytochemical fingerprinting to thwart black cohosh adulteration: a 15 <i>Actaea</i> species analysis. 2011 , 22, 339-51	37
766	Biomarkers for predicting postmenopausal coronary heart disease. 2011 , 5, 485-95	3
765	Breast Cancer Risk - Genes, Environment and Clinics. 2011 , 71, 1056-1066	45
764	Lasofloxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. 2011 , 6, 205-17	4
763	Menopausal hot flushes and vascular health. 2011 , 43, 283-91	18
762	Provision of health information for all. 2011 , 342, d4151	9
761	Improving child survival through vitamin A supplementation. 2011 , 343, d5294	6
760	Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. 2011 , 32, 1362-8	190
759	Progress in mining the human proteome for disease applications. 2011 , 15, 133-9	9

758	Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. 2011 , 20, 1007-16	25
757	Effect of dietary fiber intake on lipoprotein cholesterol levels independent of estradiol in healthy premenopausal women. 2011 , 173, 145-56	26
756	Update in hormone therapy use in menopause. 2011 , 96, 255-64	92
755	Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. 2011 , 6, 1591-8	18
754	Benefits and risks during HRT: main safety issue breast cancer. 2011 , 5, 105-16	5
753	Estrogen replacement attenuates exaggerated neointimal hyperplasia following carotid endarterectomy in rats. 2011 , 45, 720-6	1
752	Estrogen receptor-alpha gene polymorphisms and body composition in children and adolescents. 2011 , 76, 86-92	5
751	Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. 2011 , 45, 499-509	9
750	Sex differences in the risk of cardiovascular disease. 2011 , 343, d5526	6
749	Estimation of the 2-sample hazard ratio function using a semiparametric model. 2011 , 12, 354-68	10
748	Estrogen receptor polymorphisms and the vascular effects of hormone therapy. 2011 , 31, 464-9	20
747	2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 , 143, e112-175	365
746	Increased leukocyte ABCA1 gene expression in post-menopausal women on hormone replacement therapy. 2011 , 27, 701-5	13
745	The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. 2011 , 22, 503-514	45
744	Local delivery of a PKC ϵ -activating peptide limits ischemia reperfusion injury in the aged female rat heart. 2011 , 301, R1242-9	20
743	Short-term oral progesterone administration antagonizes the effect of transdermal estradiol on endothelium-dependent vasodilation in young healthy women. 2011 , 301, H1716-22	40
742	A randomised controlled trial of cognitive-behavioural therapy for women with problematic menopausal hot flushes: MENOS 2 trial protocol. 2011 , 1, e000047	7
741	Aging and estrogen alter endothelial reactivity to reactive oxygen species in coronary arterioles. 2011 , 300, H2105-15	44

740	Coronary arterial calcification and thoracic spine mineral density in early menopause. 2011 , 14, 438-44	7
739	Effects of early initiated oestrogen replacement therapy on plasma homocysteine levels in women in surgically induced menopause. 2011 , 27, 101-6	1
738	Chronic estradiol-17 β exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. 2011 , 300, R1560-8	22
737	Acupuncture for hot flashes in perimenopausal and postmenopausal women: a randomised, sham-controlled trial. 2011 , 29, 249-56	42
736	The effect of acupuncture on postmenopausal symptoms and reproductive hormones: a sham controlled clinical trial. 2011 , 29, 27-31	39
735	Effects of testosterone and 17 β -oestradiol on expression of the G protein-coupled receptor P2Y12 in megakaryocytic DAMI cells. 2012 , 23, 579-85	9
734	Shock, terror and controversy: how the media reacted to the Women's Health Initiative. 2012 , 15, 275-80	14
733	Do extracts of oral soybean augment the trophic effect of estrogen on the rat uterus?. 2013 , 16, 161-8	10
732	Is there a future for selective estrogen-receptor modulators in osteoporosis?. 2012 , 4, 55-9	2
731	Effects of estrogen on cardiovascular injury in ovariectomized female DahlS.Z-Lepr(fa)/Lepr(fa) rats as a new animal model of metabolic syndrome. 2012 , 59, 694-704	30
730	Dydrogesterone exerts endothelial anti-inflammatory actions decreasing expression of leukocyte adhesion molecules. 2012 , 18, 44-51	4
729	Changing concepts: Menopausal hormone therapy and breast cancer. 2012 , 104, 517-27	105
728	Inclusion of stroke in cardiovascular risk prediction instruments: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i> , 2012 , 43, 1998-2027	6,7 105
727	Perceived control and hot flashes in treatment-seeking breast cancer survivors and menopausal women. 2012 , 35, 195-202	8
726	The effects of 17 β -oestradiol on increased α 1-adrenergic vascular reactivity induced by prolonged ovarian hormone deprivation: the role of voltage-dependent L-type Ca channels. 2012 , 90, 316-23	2
725	Protein restriction during pregnancy induces hypertension in adult female rat offspring--influence of oestradiol. 2012 , 107, 665-73	30
724	Lipocalin 2 deficiency alters estradiol production and estrogen receptor signaling in female mice. 2012 , 153, 1183-93	38
723	Endothelial function is impaired across the stages of the menopause transition in healthy women. 2012 , 97, 4692-700	151

722	Quantitative proteomic analysis reveals novel mitochondrial targets of estrogen deficiency in the aged female rat heart. 2012 , 44, 957-69	30
721	Assessing causal relationships between treatments and clinical outcomes: always read the fine print. 2012 , 47, 626-32	3
720	Does the evidence for an inverse relationship between serum vitamin D status and breast cancer risk satisfy the Hill criteria?. 2012 , 4, 152-7	27
719	Estrogen attenuates coupling factor 6-induced salt-sensitive hypertension and cardiac systolic dysfunction in mice. 2012 , 35, 539-46	13
718	Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy. 2012 , 126, 1577-86	17
717	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2012 , 126, e354-471	268
716	Have we come full circle - or moved forward? The Women's Health Initiative 10 years on. 2012 , 15, 206-12	28
715	Vascular disease in diabetic women: Why do they miss the female protection?. 2012 , 2012, 570598	29
714	Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. 2012 , 15, 350-7	24
713	Stellate-ganglion block as a treatment for severe postmenopausal flushing. 2013 , 16, 41-7	25
712	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2012 , 126, e354-471	537
711	Anti-inflammatory approaches to reduce acute cardiovascular events: not only benefits. 2012 , 13, 27-36	
710	Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. 2012 , 19, 749-59	109
709	The 2012 hormone therapy position statement of: The North American Menopause Society. 2012 , 19, 257-71	489
708	Vascular effects of estrogenic menopausal hormone therapy. 2012 , 7, 47-70	65
707	A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause. 2012 , 19, 54-61	37
706	Vasomotor hot flashes and heart rate variability: a placebo-controlled trial of postmenopausal hormone therapy. 2012 , 19, 82-8	18
705	Pharmaceuticals. 2012 , 583-602	

704	The soy isoflavone genistein inhibits the reduction in Achilles tendon collagen content induced by ovariectomy in rats. 2012 , 22, e108-14	14
703	The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. 2012 , 15, 217-28	58
702	Design of Clinical Studies and Trials. 2012 , 225-242	4
701	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2012 , 60, e44-e164	139
700	2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 2012 , 60, e44-e164	1138
699	Bioactive compounds with effects on inflammation markers in humans. 2012 , 63, 749-65	41
698	Comments on Lauer's 'How the debate about comparative effectiveness research should impact the future of clinical trials'. 2012 , 31, 3060-1; discussion 3066-7	
697	Estrogen decrease coronary artery disease risk in patients with cervical cancer after treatment. 2012 , 127, 186-90	3
696	[Menopause and cardiovascular risk]. 2012 , 41, F13-9	13
695	Tratamiento de las dislipemias en situaciones especiales. 2012 , 12, 26-32	
694	Changing focus: women's perimenopausal journey. 2012 , 33, 540-59	4
693	Perimenopausal regulation of steroidogenesis in the nonhuman primate. 2012 , 33, 1487.e1-13	29
692	Ovariectomy enhances SR Ca ²⁺ release and increases Ca ²⁺ spark amplitudes in isolated ventricular myocytes. 2012 , 52, 32-42	33
691	'Gain'-ful insight into the cardiomyocyte Ca ²⁺ seX factor. 2012 , 52, 7-9	6
690	Uterine cells are recruited to the infarcted heart and improve cardiac outcomes in female rats. 2012 , 52, 1265-73	9
689	[Surrogate end points--somewhere between essential and not worth discussing]. 2012 , 106, 161-7	
688	Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy. 2012 , 15, 299-305	12
687	Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. 2012 , 175, 250-62	157

686	Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. 2012 , 121-139.e6	4
685	Effect of hot flushes on cardiovascular autonomic responsiveness: a randomized controlled trial on hormone therapy. 2012 , 72, 243-8	7
684	Pelvic inflammatory disease and myocardial infarction. 2012 , 158, 463	1
683	Carbon monoxide exposure in the urban environment: an insidious foe for the heart?. 2012 , 184, 204-12	27
682	The history of hormone therapy use and recent controversy related to heart disease and breast cancer arising from prevention trial outcomes. 2012 , 57, 547-557	5
681	Long term hormone therapy for perimenopausal and postmenopausal women. 2012 , CD004143	102
680	Nonhuman Primate Models of Atherosclerosis. 2012 , 385-411	4
679	Hormone therapy increases risk of ulcerative colitis but not Crohn's disease. 2012 , 143, 1199-1206	77
678	Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. 2012 , 60, 569-80	34
677	Dietary genistein induces sex-dependent effects on murine body weight, serum profiles, and vascular function of thoracic aortae. 2012 , 9, 295-308	15
676	Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice. 2012 , 9, 319-28	15
675	Neuroprotection and estrogen receptors. 2012 , 96, 119-30	68
674	Cardiac Ageing and Systemic Disorders. 2012 , 405-412	
673	Design of Observational Studies. 2012 , 207-223	0
672	What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. 2012 , 15 Suppl 1, 3-10	42
671	Management of hypertension in women. 2012 , 35, 251-60	23
670	Cohort profile: design and methods of the PREDIMED study. 2012 , 41, 377-85	369
669	Anemia and Cardiovascular Risk in the Kidney Disease Patients: What Is the Best Way to Achieve and What Is the Desired Hemoglobin?. 2012 , 13-24	

668	Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: A sex-specific relation?. 2012 , 98, 75-85	42
667	The Kidney in Heart Failure. 2012 ,	
666	Rapid changes in cardiac myofilament function following the acute activation of estrogen receptor-alpha. 2012 , 7, e41076	19
665	Pharmacovigilance and Principle of Nonmaleficence in Sex Reassignment. 2012 , 48, 88	
664	Cognitive behavioral interventions for the treatment of menopausal symptoms. 2012 , 7, 321-326	3
663	Development and Conduct of Studies. 2012 , 381-394	
662	Metabolic surgery for type 2 diabetes. 2012 , 18, 656-8	25
661	Protective inflammasome activation in AMD. 2012 , 18, 658-60	8
660	Are all estrogens created equal? A review of oral vs. transdermal therapy. 2012 , 21, 161-9	69
659	Risk stratification of CAD with SPECT-MPI in women with known estrogen status. 2012 , 19, 330-7	4
658	[Off-label therapy from the perspective of the medical insurance service]. 2012 , 71, 101-4, 106-7	0
657	Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. 2012 , 285, 1647-56	13
656	Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. 2012 , 119, 40-50	87
655	Individualizing Management for Common Concerns of Postmenopausal Women. 2012 , 8, 470-474	
654	Checking the Short-Term and Long-Term Hazard Ratio Model for Survival Data. 2012 , 39, 554-567	8
653	Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?. 2012 , 90, 22-9	19
652	Semiparametric inference on the absolute risk reduction and the restricted mean survival difference. 2013 , 19, 219-41	5
651	The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. 2013 , 62, 1313-22	5

650	An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease. 2013 , 5, 344	11
649	A prospective, case-control study on the lipid profile and the cardiovascular risk of menopausal women on oestrogen plus progestogen therapy in a northern Italy province. 2013 , 288, 91-7	7
648	Women's Health Initiative Hormone Therapy Trials: New insights on Cardiovascular Disease from Additional Years of Follow up. 2013 , 7, 196-202	10
647	17- β Oestradiol prevents cardiovascular dysfunction in post-menopausal metabolic syndrome by affecting SIRT1/AMPK/H3 acetylation. 2013 , 170, 779-95	47
646	Studies on Women's Health. 2013 ,	5
645	Do omega-3 polyunsaturated fatty acids ameliorate spinal cord injury?: Commentary on: Lim et al., Improved outcome after spinal cord compression injury in mice treated with docosahexaenoic acid. Exp. Neurol. Jan; 239:13-27. 2013 , 249, 104-10	12
644	Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. 2013 , 62, 424-34	192
643	Hormone therapy for preventing cardiovascular disease in post-menopausal women. 2013 , CD002229	18
642	Essential role of estrogen for improvements in vascular endothelial function with endurance exercise in postmenopausal women. 2013 , 98, 4507-15	98
641	Apoptosis and autophagy contribute to gender difference in cardiac ischemia-reperfusion induced injury in rats. 2013 , 93, 265-70	47
640	Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. 2013 , 310, 1353-68	811
639	Desideratum for evidence based epidemiology. 2013 , 36 Suppl 1, S5-14	18
638	Emerging evidence of the importance of rapid, non-nuclear estrogen receptor signaling in the cardiovascular system. 2013 , 78, 589-96	41
637	The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. 2013 , 62 Suppl 1, S15-9	18
636	Age-related differences in cardiac ischemia-reperfusion injury: effects of estrogen deficiency. 2013 , 465, 669-85	22
635	Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. 2013 , 34, 171-208	246
634	Pharmacotherapy: Benefits of menopausal hormone therapy--timing is key. 2013 , 9, 5-6	12
633	Estrogen receptor beta does not influence ischemic tolerance in the aged female rat heart. 2013 , 31, 32-7	15

632	NonST-Segment Elevation Acute Coronary Syndromes. 2013 , 153-177	
631	Hormone therapy in women after heart transplantation. 2013 , 45, 3386-8	2
630	The relationship between urban sprawl and coronary heart disease in women. 2013 , 20, 51-61	51
629	La secreci3n de testosterona decae naturalmente con la edad. El s3ndrome por d3ficit de testosterona es una enfermedad inventada. 2013 , 20, 580-584	
628	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 , 61, e179-347	328
627	Recomenda3es da ESC/EAS para a abordagem cl3nica das dislipidemias. 2013 , 32, 81.e1-81.e50	
626	Sex-related differences in carotid plaque features and inflammation. 2013 , 57, 338-44	40
625	A decade of reversal: an analysis of 146 contradicted medical practices. 2013 , 88, 790-8	205
624	Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog). 2013 , 1514, 12-7	56
623	Tumor necrosis factor-3inhibition improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. 2013 , 230, 390-6	48
622	Clinical management of takotsubo cardiomyopathy. 2013 , 9, 177-86, viii	16
621	Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). 2013 , 99, 1385-91	43
620	Decreased bone mineral density and periodontal management. 2013 , 61, 195-218	28
619	Postmenopausal hormone therapy: risks and benefits. 2013 , 9, 216-27	73
618	Protective actions of progesterone in the cardiovascular system: potential role of membrane progesterone receptors (mPRs) in mediating rapid effects. 2013 , 78, 583-8	43
617	Where are we 10 years after the Women's Health Initiative?. 2013 , 98, 1771-80	58
616	Storage time of red blood cells and mortality of transfusion recipients. 2013 , 27, 36-43	47
615	Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013 , 42, 227-53	5-5 49

614	Integrative Biology of Women's Health. 2013,	
613	2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. 2013, 34, 2949-3003	3076
612	Lipoprotein(a): epidemiology, atherogenic activity and impact on cardiovascular risk. 2013, 8, 195-203	2
611	Study design elements for rigorous quasi-experimental comparative effectiveness research. 2013, 2, 159-73	8
610	Menopausal hormone therapy: examining cardiovascular and clinical impacts of treatment. 2013, 9, 427-35	1
609	Should HRT be duration limited?. 2013, 19, 167-74	
608	While hormone therapy unlikely harmful in younger postmenopausal women at low CV risk, protective effects cannot be claimed. 2013, 18, 176-7	1
607	2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013, 127, e683-828	193
606	Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. 2013, 62, 957-65	50
605	Social and Cultural Factors Affecting Complementary and Alternative Medicine (CAM) Use during Menopause in Sydney and Bologna. 2013, 2013, 836234	5
604	An update on menopausal hormone replacement therapy in women and cardiovascular disease. 2013, 20, 148-55	13
603	Quality of life and hypertension after hormone therapy withdrawal in New York City. 2013, 20, 1255-63	3
602	Ovarian hormones and vascular disease. 2013, 28, 411-6	14
601	Estriol, a stimulator of nitric oxide synthesis in platelets, and its role as the powerful inhibitor of platelet aggregation. 2013, 2, 50-54	4
600	Estrogens increase cystathionine-lyase expression and decrease inflammation and oxidative stress in the myocardium of ovariectomized rats. 2013, 20, 1084-91	47
599	Progress in Women's Health Research. 2013, 107-117	
598	Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. 2013, 22, 70-96	124
597	Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation. 2013, 33, 1837-43	47

596	Invited commentary: Off-roading with social epidemiology--exploration, causation, translation. 2013 , 178, 858-63	17
595	A randomised controlled trial comparing the effects of micronized progesterone to medroxyprogesterone acetate on cardiovascular health, lipid metabolism and the coagulation cascade in women with premature ovarian insufficiency: study protocol and review of the literature. 2013 , 19, 127-32	8
594	MTHFR C677T polymorphism modifies the effect of HRT on metabolic parameters in postmenopausal women. 2013 , 16, 568-75	1
593	Results from a carotid intima-media thickness trial as a decision tool for launching a large-scale morbidity and mortality trial. 2013 , 6, 20-5	15
592	Coronary artery bypass graft surgery using the radial artery as a secondary conduit improves patient survival. 2013 , 2, e000266	11
591	Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative. 2013 , 24, 493-9	39
590	Hormonalna terapia zastępcza a cukrzyca. 2013 , 1, 63-68	
589	Efficacy of black cohosh (<i>Cimicifuga racemosa</i> L.) in treating early symptoms of menopause: a randomized clinical trial. 2013 , 8, 20	30
588	Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases. 2013 , 5, 112	19
587	Mechanisms enforcing the estrogen receptor α selectivity of botanical estrogens. 2013 , 27, 4406-18	74
586	Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. 2013 , 20, R183-201	77
585	Beta-blockers in cardiovascular medicine: still alive and kicking. 2013 , 24, 6-7	
584	Are observational studies more informative than randomized controlled trials in hypertension? Consider the side of the argument. 2013 , 62, 470-6	9
583	Genistein inhibits cell proliferation and stimulates apoptosis in human coronary artery endothelial cells. 2013 , 75, 235-42	8
582	Guidelines for the clinical application of bypass grafts and the surgical techniques (JCS 2011) published in 2012--digest version. 2013 , 77, 1608-41	5
581	ACOG Committee Opinion No. 565: Hormone therapy and heart disease. 2013 , 121, 1407-1410	28
580	Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. 2013 , 20, 372-82	29
579	Developing HRT Prescribing in Obese Women. 2013 , 537-555	

578	Socioeconomic Determinants of Women's Health. 2013 , 671-683	1
577	HORMONE REPLACEMENT THERAPY AND WOMEN'S HEALTH. 2013 , 81-109	
576	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. 2013 , 603-615	
575	Menopause. 287-324	2
574	Prevention and treatment of venous thromboembolism during HRT: current perspectives. 2014 , 7, 433-40	18
573	Women's Health Initiative Hormone Therapy Trials. 2014 , 918-930	
572	Sleep-related comorbidities in women with epilepsy. 34-49	
571	Impact of ovarian function on cardiovascular health in women: focus on hypertension. 2014 , 6, 131-9	35
570	World Health Organization (WHO): Global Health Situation. 2014 , 914-924	
569	Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. 2014 , 9, 1939-50	18
568	Gaps in menopause knowledge. 2014 , 20, 47-51	4
567	Women. Executive Summary of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan 2012 Version. 2014 , 21, 291-5	2
566	Women's Health Initiative: Statistical Aspects and Selected Early Results. 2014 ,	
565	Menopausal Hormonal Therapy and Cardiovascular Disease. 2014 , 3, 217-222	
564	Incidence and prevalence of pregnancy-related heart disease. 2014 , 101, 554-60	44
563	An investigation of the significance of residual confounding effect. 2014 , 2014, 658056	16
562	Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. 2014 , 32, 419-25	28
561	Effects of oral hormone replacement therapy on mean platelet volume in postmenopausal women. 2014 , 44, 980-4	1

560	Postmenopausal hormone therapy and coronary heart disease in early postmenopausal women. 2014 , 46, 1-7	14
559	Congress on women's health Trudy Bush lecture 2014: new insights into sex Hormones and Cardiovascular disease. 2014 , 23, 997-1004	3
558	Estrogen in cardiovascular disease during systemic lupus erythematosus. 2014 , 36, 1901-1912	12
557	Sex and haemodynamics in pulmonary arterial hypertension. 2014 , 43, 523-30	58
556	Sex hormone levels in patients with sudden cardiac arrest. 2014 , 11, 2267-72	20
555	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, e344-426	754
554	Cardiovascular risk in women with type 2 diabetes mellitus and prediabetes: is it indeed higher than men?. 2014 , 171, R245-55	18
553	Knowledge and personal use of menopausal hormone therapy among Chinese obstetrician-gynecologists: results of a survey. 2014 , 21, 1190-6	15
552	Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys. 2014 , 21, 8-14	6
551	What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead?. 2014 , 21, 769-83	9
550	Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. 2014 , 21, 260-6	65
549	Risks and benefits of hormone therapy: has medical dogma now been overturned?. 2014 , 17, 215-22	14
548	Metformin ameliorates ovariectomy-induced vascular dysfunction in non-diabetic Wistar rats. 2014 , 127, 265-75	10
547	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, 2354-94	696
546	The Cardiovascular Spectrum of Adverse Drug Reactions. 2014 , 577-584	
545	Right answers, wrong questions in clinical research. 2014 , 6, 221fs5	7
544	Gender and Cardiovascular Disease in the Post-Genomic Era. 2014 , 615-637	
543	Postmenopausal hormone replacement therapy and risk of acute pancreatitis: a prospective cohort study. 2014 , 186, 338-44	10

542	Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative. 2014 , 7, 157-62	67
541	Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women. 2014 , 17, 356-62	4
540	Sex differences in cognitive impairment and Alzheimer's disease. 2014 , 35, 385-403	252
539	Riluzole improves outcome following ischemia-reperfusion injury to the spinal cord by preventing delayed paraplegia. 2014 , 265, 302-12	39
538	Effects of estrogen and opioid blockade on blood pressure reactivity to stress in postmenopausal women. 2014 , 37, 94-101	6
537	Six persistent research misconceptions. 2014 , 29, 1060-4	253
536	Endothelial Dysfunction and Dyslipidemia in Type 2 Diabetes: Pathogenesis, Significance and Therapy. 2014 , 239-278	
535	Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy. 2014 , 34, 410-23	16
534	Prevention and treatment of postmenopausal osteoporosis. 2014 , 142, 155-70	391
533	Menopausal hormone therapy and menopausal symptoms. 2014 , 101, 905-15	91
532	Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. 2014 , 60, 68-77	38
531	The Women's Health Initiative trial and related studies: 10 years later: a clinician's view. 2014 , 142, 4-11	90
530	Current and evolving approaches to individualizing estrogen receptor-based therapy for menopausal women. 2014 , 99, 733-47	21
529	Menopausal hormone treatment cardiovascular disease: another look at an unresolved conundrum. 2014 , 101, 887-97	20
528	Androgen deficiency and type 2 diabetes mellitus. 2014 , 47, 940-9	19
527	Management of Osteoporotic Patients with Distal Radial Fractures. 2014 , 2,	2
526	Incidence of hypertension, stroke, coronary heart disease, and diabetes in women who have delivered after in vitro fertilization: a population-based cohort study from Sweden. 2014 , 102, 1096-102	29
525	Microphysiological modeling of the reproductive tract: a fertile endeavor. 2014 , 239, 1192-202	25

524	2014 AHA/ACC Guideline for the Management of Patients With NonST-Elevation Acute Coronary Syndromes: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 64, 2645-2687	132
523	G protein-coupled estrogen receptor 1 mediates relaxation of coronary arteries via cAMP/PKA-dependent activation of MLCP. 2014 , 307, E398-407	41
522	Is transdermal menopausal hormone therapy (MHT) associated with an increased cardiovascular risk?. 2014 , 290, 617-9	
521	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 64, e139-e228	1822
520	Use acupuncture to relieve perimenopausal syndrome: study protocol of a randomized controlled trial. 2014 , 15, 198	6
519	Differential regulation of endothelium behavior by progesterone and medroxyprogesterone acetate. 2014 , 220, 179-93	12
518	Strategies for treating lipids for prevention: risk stratification models with and without imaging. 2014 , 28, 295-307	2
517	Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable. 2014 , 67, 135.e1-135.e81	9
516	Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. 2014 , 2, 175-81	76
515	Selection bias in rheumatic disease research. 2014 , 10, 403-12	69
514	Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. 2014 , 161, 249-60	215
513	Interpreting clinical studies: The devil is in the detail. 2014 , 12, 406-410	
512	Implications of Gender Difference in Coronary Calcification as Assessed by CT Coronary Angiography. 2014 , 8, 51-5	10
511	OSA is common and independently associated with hypertension and increased arterial stiffness in consecutive perimenopausal women. 2014 , 146, 66-72	33
510	Managing Menopause Chapter 2 Cardiovascular Disease. 2014 , 36, S16-S22	1
509	A paradigm shift in the treatment of central sleep apnea in heart failure. 2015 , 148, 848-851	9
508	Total joint arthroplasty and the risk of myocardial infarction: a general population, propensity score-matched cohort study. 2015 , 67, 2771-9	31
507	Psychiatric Conditions During Peripartum and Perimenopause. 2015 , 2427-2438	1

506 Menopausale Hormontherapie und koronare Herzkrankheit. **2015**, 13, 257-265

505 Acute Coronary Syndrome: Current Diagnosis and Management in Women. **2015**, 9, 1

504 Assessing potentially time-dependent treatment effect from clinical trials and observational studies for survival data, with applications to the Women's Health Initiative combined hormone therapy trial. **2015**, 34, 1801-17 9

503 Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence. **2015**, 22, 495-501 10

502 Enhanced Estrogenic Activity of Soybean Isoflavones by Coadministration of Liuwei Dihuang Pills in Ovariectomized Rats. **2015**, 29, 1054-61 8

501 Does menopausal hormone therapy reduce myocardial infarction risk if initiated early after menopause? A population-based case-control study. **2015**, 22, 598-606 9

500 Update on menopausal hormone therapy. **2015**, 22, 475-82 3

499 Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. **2015**, 50, 1432-51 30

498 How Do You Know Which Health Care Effectiveness Research You Can Trust? A Guide to Study Design for the Perplexed. **2015**, 12, E101 57

497 A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. **2015**, 2015, 713295 9

496 Effects of the Chinese Herbal Formulation (Liu Wei Di Huang Wan) on the Pharmacokinetics of Isoflavones in Postmenopausal Women. **2015**, 2015, 902702 7

495 Relationship between Postmenopausal Estrogen Deficiency and Aneurysmal Subarachnoid Hemorrhage. **2015**, 2015, 720141 22

494 Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures. **2015**, 27, 9-16 2

493 The menstrual cycle's SWAN song. **2015**, 22, 256-7

492 Sex matters to the heart: A special issue dedicated to the impact of sex related differences of cardiovascular diseases. **2015**, 241, 205-7 25

491 Cardiovascular Prevention at the Menopausal Transition: Role of Hormonal Therapies. **2015**, 157-165

490 Correlates of Peripheral Blood Mitochondrial DNA Content in a General Population. **2016**, 183, 138-46 63

489 Evidence-Based Medicine, Postmenopausal Hormone Therapy, and the Women's Health Initiative. **2015**, 2, 1-17 1

488	Increased high-density lipoprotein cholesterol levels in mice with XX versus XY sex chromosomes. 2015 , 35, 1778-86	49
487	Psychosocial Stress and Cardiovascular Disease in Women. 2015 ,	1
486	Estrogen receptor β gene (ESR1) PvuII and XbaI polymorphisms are associated to metabolic and proinflammatory factors in polycystic ovary syndrome. 2015 , 560, 44-9	17
485	Sex hormone replacement in ovarian failure - new treatment concepts. 2015 , 29, 105-14	31
484	Comparative effects of estrogen, raloxifene and tamoxifen on endothelial dysfunction, inflammatory markers and oxidative stress in ovariectomized rats. 2015 , 124, 101-9	44
483	Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event?. 2015 , 291, 213-7	8
482	Hormone therapy for preventing cardiovascular disease in post-menopausal women. 2015 , CD002229	134
481	Conflicts of interest, smoke and mirrors. 2015 , 18, 348-9	0
480	Contributions of risk factors and medical care to cardiovascular mortality trends. 2015 , 12, 508-30	163
479	Gender specific generation of nitroxyl (HNO) from rat endothelium. 2015 , 71, 208-14	6
478	Cimicifuga racemosa extract for relieving menopausal symptoms: a randomized controlled trial. 2015 , 18, 79-85	18
477	Alveolar bone dynamics in osteoporotic rats treated with raloxifene or alendronate: confocal microscopy analysis. 2015 , 20, 038003	14
476	Targeting lipoprotein (a): an evolving therapeutic landscape. 2015 , 17, 502	7
475	Iron, inflammation and atherosclerosis risk in men vs. perimenopausal women. 2015 , 241, 249-54	8
474	Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. 2015 , 11, 239-257	67
473	Psychoneuroimmunological Pathways and Sex Differences in Coronary Artery Disease: The Role of Inflammation and Estrogen. 2015 , 129-149	1
472	Relationship between age at natural menopause and risk of heart failure. 2015 , 22, 12-6	44
471	European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. 2015 , 39 Suppl 1, S107-19	31

470	Is tree loss associated with cardiovascular-disease risk in the Women's Health Initiative? A natural experiment. 2015 , 36, 1-7	57
469	Methodological considerations of the GRADE method. 2015 , 47, 1-5	25
468	Counterpoint: epidemiology to guide decision-making: moving away from practice-free research. 2015 , 182, 834-9	35
467	Appropriate models for novel osteoporosis drug discovery and future perspectives. 2015 , 10, 1201-16	18
466	Folate, vitamin B-6, and vitamin B-12 intake and mild cognitive impairment and probable dementia in the Women's Health Initiative Memory Study. 2015 , 115, 231-241	51
465	Comprehensive Management of High Risk Cardiovascular Patients. 2016 ,	1
464	Extracellular Release and Signaling by Heat Shock Protein 27: Role in Modifying Vascular Inflammation. 2016 , 7, 285	73
463	Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials. 2016 , 129, 215-26	44
462	Acupuncture in Menopause (AIM) study: a pragmatic, randomized controlled trial. 2016 , 23, 626-37	39
461	Increasing use of prescription drugs in the United Kingdom. 2016 , 25, 628-36	20
460	A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine granules for the treatment of menopausal symptoms by stages. 2016 , 23, 311-23	17
459	Arterial Thrombosis. 2016 , 229-239	
458	Propensity Score: an Alternative Method of Analyzing Treatment Effects. 2016 , 113, 597-603	72
457	Bariatric surgery and fractures. 2016 , 354, i4057	1
456	Principles of Transgender Medicine and Surgery. 2016 ,	33
455	Postmenopausal Hormone Therapy and Atherosclerosis--Time Is of the Essence. <i>New England Journal of Medicine</i> , 2016 , 374, 1279-80	59.2 23
454	Treatment needs and current options for postmenopausal osteoporosis. 2016 , 17, 1141-52	52
453	Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. 2016 , 48, 33-41	20

452	Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis. 2016 , 32, 685-689	6
451	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). 2016 , 253, 281-344	519
450	Causal inference challenges in social epidemiology: Bias, specificity, and imagination. 2016 , 166, 258-265	11
449	Evaluating the Role of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease. 2016 , 33, 787-808	10
448	Exogenous Hormone Use: Oral Contraceptives, Postmenopausal Hormone Therapy, and Health Outcomes in the Nurses' Health Study. 2016 , 106, 1631-7	32
447	2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. 2016 , 37, 2999-3058	1781
446	Progestogen safety and tolerance in hormonal replacement therapy. 2016 , 15, 1515-1525	13
445	Essentials in Stable Angina Pectoris. 2016 ,	
444	[Antiplatelet therapy in women: A gender-specificity?]. 2016 , 65, 395-403	1
443	Reduction of apoptosis and preservation of mitochondrial integrity under ischemia/reperfusion injury is mediated by estrogen receptor α . 2016 , 7, 53	26
442	Cardiovascular risk assessment in women - an update. 2016 , 19, 329-36	45
441	Strategies and methods to study female-specific cardiovascular health and disease: a guide for clinical scientists. 2016 , 7, 19	32
440	Reproductive Factors Predicting Angiographic Obstructive Coronary Artery Disease: The KoRean wOmen'S Chest Pain rEgistry (KoROSE). 2016 , 25, 443-8	7
439	Pause menopause with Rhodiola rosea, a natural selective estrogen receptor modulator. 2016 , 23, 763-9	21
438	Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy. 2016 , 36, 418-24	4
437	Risk of Inflammatory Bowel Disease with Oral Contraceptives and Menopausal Hormone Therapy: Current Evidence and Future Directions. 2016 , 39, 193-7	21
436	Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. 2016 , 39, 807-34	31
435	Early menopause does not influence left ventricular diastolic dysfunction: A clinical observational study in healthy subjects. 2016 , 68, 548-553	8

434	Association of Serum Sex Hormones with Hemostatic Factors in Women On and Off Hormone Therapy: The Multiethnic Study of Atherosclerosis. 2016 , 25, 166-72	8
433	Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT. 2016 , 27, 40-3	17
432	Osteoporosis. 2016 , 1184-1213.e6	1
431	Long-term hormone therapy for perimenopausal and postmenopausal women. 2017 , 1, CD004143	110
430	Drug Therapy for Stable Angina Pectoris. 2017 , 77, 265-284	20
429	Targeted basic research to highlight the role of estrogen and estrogen receptors in the cardiovascular system. 2017 , 119, 27-35	27
428	Gender differences in cardiovascular prophylaxis: Focus on antiplatelet treatment. 2017 , 119, 36-47	27
427	Menopausal Hormone Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. 2017 , 152, 1915-1921.e1	13
426	Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases. 2017 , 37, 746-756	142
425	Extended versus Standard Pelvic Lymph Node Dissection in Radical Prostatectomy on Oncological and Functional Outcomes: A Systematic Review and Meta-Analysis. 2017 , 24, 2047-2054	30
424	The evidence base for HRT: what can we believe?. 2017 , 20, 91-96	47
423	Obesity Surgery and the Risk of Colorectal Carcinoma-Searching for the Fly in the Ointment?. 2017 , 265, e29-e30	5
422	Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review. 2017 , 42, 266-305	9
421	Stroke in Women: Risk Factors and Clinical Biomarkers. 2017 , 118, 4191-4202	59
420	Sex differences in sympathetic vasoconstrictor responsiveness and sympatholysis. 2017 , 123, 128-135	9
419	Sex Hormones and Cardiometabolic Health: Role of Estrogen and Estrogen Receptors. 2017 , 158, 1095-1105	56
418	Oestrogen and anti-androgen therapy for transgender women. 2017 , 5, 291-300	93
417	Gonadal Steroid Hormones and Brain Protection. 2017 , 355-376	

416	Lipoprotein(a): A Lipoprotein Whose Time Has Come. 2017 , 19, 48	9
415	Safety and benefit considerations for menopausal hormone therapy. 2017 , 16, 941-954	9
414	The Women's Health Initiative: evolving insights over 15 years. 2017 , 24, 355-357	6
413	Gender differences in the effects of cardiovascular drugs. 2017 , 3, 163-182	126
412	New evidence for cardiac benefit of postmenopausal hormone therapy. 2017 , 20, 5-10	8
411	Alcohol Consumption and Cardiac Disease: Where Are We Now?. 2017 , 69, 25-27	11
410	Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. 2017 , 103, 1954-1961	18
409	Emodin promotes the osteogenesis of MC3T3-E1 cells via BMP-9/Smad pathway and exerts a preventive effect in ovariectomized rats. 2017 , 49, 867-878	13
408	Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: A narrative review. 2017 , 104, 44-53	20
407	Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. 2017 , 24, 1101-1112	8
406	Vasomotor hot flashes and cardiac repolarization: a randomized placebo-controlled trial of postmenopausal hormone therapy. 2017 , 24, 1386-1391	
405	Age of menarche is associated with knee joint replacement due to primary osteoarthritis (The HUNT Study and the Norwegian Arthroplasty Register). 2017 , 25, 1654-1662	8
404	Discussion: Is the FDA in need of a major change in the way it regulates?. 2017 , 18, 414-416	1
403	Words Matter: Researchers Should Avoid Implying Causation in Studies of Association. 2017 , 70, 262-263	
402	The impact of ovariectomy on cardiac excitation-contraction coupling is mediated through cAMP/PKA-dependent mechanisms. 2017 , 111, 51-60	16
401	Postmenopausale Hormonersatztherapie und vaskuläres Risiko. 2017 , 50, 579-585	
400	Trajectories of response to acupuncture for menopausal vasomotor symptoms: the Acupuncture in Menopause study. 2017 , 24, 171-179	9
399	An update on hormone therapy in postmenopausal women: mini-review for the basic scientist. 2017 , 313, H1013-H1021	42

398	Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. 2017 , 20, 402-413	17
397	The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis. 2017 , 6, 452-463	25
396	Hormone Replacement: The Fountain of Youth?. 2017 , 44, 481-498	5
395	Role of Estrogens in the Regulation of Liver Lipid Metabolism. 2017 , 1043, 227-256	148
394	Exploring Selection Bias by Causal Frailty Models: The Magnitude Matters. 2017 , 28, 379-386	17
393	Ovarian Lipid Metabolism Modulates Circulating Lipids in Premenopausal Women. 2017 , 102, 3138-3145	8
392	Outcome-wide Epidemiology. 2017 , 28, 399-402	73
391	Effect of Gua sha therapy on perimenopausal syndrome: a randomized controlled trial. 2017 , 24, 299-307	10
390	Ovary as a Biomarker of Health and Longevity: Insights from Genetics. 2017 , 35, 231-240	8
389	A novel mechanism of non-feminizing estrogens in neuroprotection. 2017 , 94, 99-102	6
388	Commentary : The value of intraoperative neurophysiological monitoring: evidence, equipoise and outcomes. 2017 , 31, 657-664	4
387	Proteomic analysis of tears following acupuncture treatment for menopausal dry eye disease by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry. 2017 , 12, 1663-1671	25
386	Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice. 2017 , 2017, 2564787	0
385	Patient-Oriented Research. 2017 , 9-23	1
384	Postmenopausale Hormonersatztherapie und vaskuläres Risiko. 2017 , 15, 243-248	
383	Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials. 2018 , 25, 753-761	23
382	Health and Cardiometabolic Disease in Transgender Adults in the United States: Behavioral Risk Factor Surveillance System 2015. 2018 , 2, 349-360	22
381	Differential Effects of Estrogen and Progestin on Apolipoprotein B100 and B48 Kinetics in Postmenopausal Women. 2018 , 53, 167-175	2

380	Therapeutic Approaches to Secondary Fracture Prevention in High Risk Populations: Current Recommendations and Advances. 2018 , 25, e104-e114	
379	Oral hormonal therapy with ethinylestradiol-levonorgestrel improves insulin resistance, obesity, and glycogen synthase kinase-3 independent of circulating mineralocorticoid in estrogen-deficient rats. 2018 , 96, 577-586	11
378	Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. 2018 , 137, e30-e66	300
377	Sex Hormone Contributes to Sexually Dimorphic Susceptibility in CVB3-Induced Viral Myocarditis via Modulating IFN- γ Cell Production. 2018 , 34, 492-501	4
376	Corni fructus ameliorates menopause symptom in 4-vinylcyclohexene diepoxide. 2018 , 14, 35-42	1
375	Gua Sha therapy for treating perimenopausal syndrome: Protocol for a systematic review. 2018 , 17, 40-44	2
374	Lessons learned from rheumatoid arthritis registries. 2018 , 85, 271-274	5
373	Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. 2018 , 198, 108-114	1
372	Les enseignements apportés par les registres de la polyarthrite rhumatoïde. 2018 , 85, 57-60	
371	The role of obesity in carotid plaque instability: interaction with age, gender, and cardiovascular risk factors. 2018 , 17, 46	22
370	Coronary artery disease after menopause and the role of estrogen replacement therapy. 2018 , 19 Suppl 1, e107-e111	1
369	Effects of Gua Sha therapy on perimenopausal syndrome: A systematic review and meta-analysis of randomized controlled trials. 2018 , 31, 268-277	8
368	Endometrial Hyperplasia, Estrogen Therapy, and the Prevention of Endometrial Cancer. 2018 , 105-120.e6	
367	Symptomatic Fibroids as Main Indication for Laparoscopic Hysterectomy and Their Handling. 2018 , 413-427	
366	Menopausal Hormone Therapy and Cardiovascular Disease: Unraveling the Role of Age and Time Since Menopause Onset. 2018 , 64, 861-862	3
365	Coronary Disease Survival with Diabetes. 2018 , 139, 40-42	
364	The Epistemological Weight of Randomized-Controlled Trials Depends on Their Results. 2018 , 61, 157-173	1
363	Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. 2018 , 25, 1262-1274	14

362	Carnosic Acid Modulates Increased Hepatic Lipogenesis and Adipocytes Differentiation in Ovariectomized Mice Fed Normal or High-Fat Diets. 2018 , 10,	9
361	Age of Postmenopause Women: Effect of Soy Isoflavone in Lipoprotein and Inflammation Markers. 2018 , 24, 176-182	8
360	Menopausal Hormone Therapy. 2018 , 381-389	
359	Quasi-experimental causality in neuroscience and behavioural research. 2018 , 2, 891-898	32
358	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis-Results From the Nurses' Health Study. 2018 , 155, 1764-1775.e2	17
357	Estrogen modulates serotonin effects on vasoconstriction through Src inhibition. 2018 , 50, 1-9	10
356	Evidence reversal: Towards awareness of the phenomenon in library and information science. 2018 , 34, 301-304	1
355	Working Together to Address Women's Health in Research and Drug Development: Summary of the 2017 Women's Health Congress Preconference Symposium. 2018 , 27, 1195-1203	3
354	Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?. 2018 , 19,	16
353	Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. 2018 , 25, 846-984	295
352	A heartfelt message, estrogen replacement therapy: use it or lose it. 2018 , 315, H1765-H1778	8
351	Sex differences in the vascular function and related mechanisms: role of 17 β -estradiol. 2018 , 315, H1499-H1518	6
350	Selective Estrogen Receptor Modulator and prostimulatory effects of phytoestrogen β -ecdysone in <i>Tinospora cordifolia</i> on osteoblast cells. 2018 , 9, 161-168	7
349	Improving reproducibility by using high-throughput observational studies with empirical calibration. 2018 , 376,	29
348	Membrane-Initiated Estrogen Receptor Signaling Mediates Metabolic Homeostasis via Central Activation of Protein Phosphatase 2A. 2018 , 67, 1524-1537	12
347	Sex differences in lipid and lipoprotein metabolism. 2018 , 15, 45-55	163
346	Steroid Hormone Vitamin D: Implications for Cardiovascular Disease. 2018 , 122, 1576-1585	31
345	Design of Observational Studies. 2018 , 231-248	5

344	Design of Clinical Trials and Studies. 2018 , 249-268	3
343	Evidence-Based Approach in Translational Dental Research. 2018 , 81-101	4
342	Quality of health economic evaluations for the ACC/AHA stable ischemic heart disease practice guideline: A systematic review. 2018 , 204, 17-33	4
341	Activation of PI3K/Akt pathway mediated by estrogen receptors accounts for estrone-induced vascular activation of cGMP signaling. 2018 , 110, 42-48	12
340	Acute Myocardial Infarction During Pregnancy and the Puerperium in the United States. 2018 , 93, 1404-1414	50
339	Clinical Knowledge from Observational Studies. Everything You Wanted to Know but Were Afraid to Ask. 2018 , 198, 859-867	29
338	Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. 2018 , 171, 95-101	7
337	Angina in Patients with Evidence of Myocardial Ischemia and No Obstructive Coronary Artery Disease. 2018 , 374-390	
336	Hormone therapy should not be prescribed for primary prevention of chronic medical conditions in asymptomatic postmenopausal women. 2018 , 23, 231-232	0
335	Development and Conduct of Studies. 2018 , 203-218	
334	Managing Menopause by Combining Evidence With Clinical Judgment. 2018 , 61, 470-479	3
333	Hormonal Management for Transfeminine Individuals. 2018 , 45, 313-317	6
332	Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance. 2018 , 361, k2139	129
331	Translational Oral Health Research. 2018 ,	2
330	Hormonersatztherapie und vaskuläres Risiko. 2019 , 22, 10-13	
329	Pharmacotherapeutic approaches to treating depression during the perimenopause. 2019 , 20, 1837-1845	3
328	Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women. 2019 , 597, 4873-4886	17
327	BMS consensus statement for primary prevention of coronary heart disease in women. 2019 , 25, 64-69	1

326	Prevention of Osteoporosis in the Ovariectomized Rat by Oral Administration of a Nutraceutical Combination That Stimulates Nitric Oxide Production. 2019 , 2019, 1592328	5
325	Female sex hormones and risk of incident abdominal aortic aneurysm in Norwegian women in the HUNT study. 2019 , 70, 1436-1445.e2	4
324	Sex hormones, aging and cardiometabolic syndrome. 2019 , 10, 30	32
323	Chapitre 2 : Maladies cardiovasculaires. 2019 , 41 Suppl 1, S49-S57	
322	HRT in der Peri- und Postmenopause. 2019 , 24, 38-46	
321	Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies. 2019 , 44-59	3
320	Chronic Disease and Social Work. 2019 , 463-497	
319	What Is Pharmacoepidemiology?. 2019 , 1-26	7
318	Biostatistics: a fundamental discipline at the core of modern health data science. 2019 , 211, 444-446.e1	2
317	Somewhere over the sex differences rainbow of myocardial infarction remodeling: hormones, chromosomes, inflammasome, oh my. 2019 , 16, 933-940	3
316	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. 2019 , 290, 140-205	259
315	Sex Differences in Circulating Biomarkers of Cardiovascular Disease. 2019 , 74, 1543-1553	37
314	Avoidable flaws in observational analyses: an application to statins and cancer. 2019 , 25, 1601-1606	76
313	Reply. 2019 , 80, e84	
312	Nutrition and venous thrombosis: An exercise in thinking about survivor bias. 2019 , 3, 6-8	
311	Acute Myocardial Infarction During Pregnancy and the Puerperium: Experiences and Challenges From Southern India. 2019 , 94, 918-919	
310	The Role of 17 β -Estradiol and Estrogen Receptors in Regulation of Ca Channels and Mitochondrial Function in Cardiomyocytes. 2019 , 10, 310	29
309	Acupuncture or phy(F)itoestrogens (E)strogen plus progestin on menopausal symptoms. A randomized study. 2019 , 35, 995-998	9

308	Combined low-dose LiCl and LY294002 for the treatment of osteoporosis in ovariectomized rats. 2019 , 14, 177	11
307	Clinical Interpretation of High-Sensitivity Troponin Testing-Reply. 2019 , 179, 726	1
306	Estrogen Receptor Signaling and Cardiovascular Function. 2019 , 13-22	1
305	A pooled analysis of three studies of nonpharmacological interventions for menopausal hot flashes. 2019 , 26, 350-356	4
304	Menopause and its Cardiometabolic Consequences: Current Perspectives. 2019 , 17, 543-545	2
303	Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases. 2019 , 15, 329-339	20
302	Promoting Health Equity through De-Implementation Research. 2019 , 29, 93-96	15
301	Risks and benefits of menopausal hormone therapy. 2019 , 62, 150	
300	Sex as a biological variable in the pathology and pharmacology of neurodegenerative and neurovascular diseases. 2019 , 176, 4173-4192	19
299	Transfeminine Hormone Therapy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019 , 48, 341-355	8
298	Evaluating Community-Based Translational Interventions Using Historical Controls: Propensity Score vs. Disease Risk Score Approach. 2019 , 20, 598-608	1
297	Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats. 2019 , 20, 1470320319895933	
296	. 2019 ,	2
295	Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol. 2019 , 29, 151-166	29
294	Effects of Gender-Affirming Hormones on Lipid, Metabolic, and Cardiac Surrogate Blood Markers in Transgender Persons. 2019 , 65, 119-134	36
293	Endocrinology of Transgender Medicine. 2019 , 40, 97-117	97
292	Ameliorative effect of low-dose spironolactone on obesity and insulin resistance is through replenishment of estrogen in ovariectomized rats. 2019 , 97, 65-74	2
291	Sex differences in gene expression in response to ischemia in the human left ventricular myocardium. 2019 , 28, 1682-1693	18

290	Unstable Angina and Non-ST Elevation Myocardial Infarction. 2019 , 233-259	
289	Aging, the menopausal transition, and hormone replenishment therapy: retrieval of confidence and compliance. 2019 , 1440, 5-22	4
288	Phytochemicals and Hormonal Effects. 2019 , 550-560	3
287	Thrombotic Risk of Contraceptives and Other Hormonal Therapies. 2019 , 637-650	
286	What Properties Might Statistical Inferences Reasonably be Expected to Have? Crisis and Resolution in Statistical Inference. 2019 , 73, 243-252	4
285	Time for Well-Powered Controlled Prospective Studies to Test a Causal Role for Herpes Viruses in Alzheimer's Disease Using Antiherpetic Drugs. 2020 , 75, 1058-1060	2
284	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. 2020 , 41, 407-477	1835
283	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020 , 41, 111-188	2236
282	The pharmacology of selective estrogen receptor modulators: past and present. 2020 , 863-893	
281	Examining the Use of Real-World Evidence in the Regulatory Process. 2020 , 107, 843-852	29
280	Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials. 2020 , 26, 2-12	11
279	The hypertensive potential of estrogen: An untold story. 2020 , 124, 106600	9
278	Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome. 2020 , 41, 1328-1336	67
277	Hormonersatztherapie und vaskuläres Risiko. 2020 , 53, 25-28	
276	Methodological considerations when analysing and interpreting real-world data. 2020 , 59, 14-25	21
275	Real-world evidence: the devil is in the detail. 2020 , 63, 1694-1705	11
274	Peri- and postmenopause-diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version. 2020 , 302, 763-777	3
273	The biological basis of sex and its role as a determinant of myocardial function in health and disease. 2020 , 5-19	

272	Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. 2020 , 142, e506-e532	90
271	Improvement in cardiac function of ovariectomized rats by antioxidant tempol. 2020 , 160, 239-245	3
270	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. 2020 , 80, 1537-1552	16
269	Trust in the Time of COVID-19. 2020 , 133, 1370-1371	1
268	Beneficial Effects of Breastfeeding on the Prevention of Metabolic Syndrome Among Postmenopausal Women. 2020 , 14, 173-177	3
267	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. 2020 , 105,	26
266	Tetragonia tetragonoides (Pall.) Kuntze Restores Blood Perfusion from Hind-Limb Ischemic Mice. 2020 , 10, 8562	
265	Arterial and venous thrombosis: What's the link? A narrative review. 2020 , 191, 97-102	11
264	Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. 2020 , 9,	23
263	Public health guidelines should recommend reducing saturated fat consumption as much as possible: NO. 2020 , 112, 19-24	15
262	Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. 2020 , 76, 844-857	128
261	The efficacy and safety of acupuncture for perimenopause symptom compared with different sham acupuncture control groups: A protocol of systematic review and meta-analysis. 2020 , 99, e19366	1
260	Sex-Specific Determinants of Coronary Artery Disease and Atherosclerotic Risk Factors: Estrogen and Beyond. 2020 , 36, 706-711	6
259	Why Test for Proportional Hazards?. 2020 , 323, 1401-1402	64
258	A deeper analysis in thyroid research: A meta-epidemiological study of the American Thyroid Association clinical guidelines. 2020 , 15, e0234297	0
257	Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?. 2020 , 31, 2271-2286	20
256	Highlights of the San Antonio Breast Cancer Symposium 2019 Part 1: the challenges of tumor heterogeneity. 2020 , 16, 1497-1502	
255	The benefit of early survival on PD versus HD-Why this is (still) very important. 2020 , 40, 405-418	8

254	Sex differences in non-obstructive coronary artery disease. 2020 , 116, 829-840	24
253	Regulatory Actions of Estrogen Receptor Signaling in the Cardiovascular System. 2019 , 10, 909	17
252	Premature Menopause and Risk for Cardiovascular Disease-Reply. 2020 , 323, 1617-1618	
251	Hormonersatztherapie und Prävention gemäß S3-Leitlinie. 2020 , 53, 161-166	
250	Hormonersatztherapie und Prävention gemäß S3-Leitlinie. 2020 , 18, 14-20	0
249	Hormonersatztherapie und vaskuläres Risiko. 2020 , 18, 16-19	
248	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. 2020 , 126, 94-102	8
247	Myocardium Metabolism in Physiological and Pathophysiological States: Implications of Epicardial Adipose Tissue and Potential Therapeutic Targets. 2020 , 21,	8
246	Estrogen Signaling in Alzheimer's Disease: Molecular Insights and Therapeutic Targets for Alzheimer's Dementia. 2020 , 57, 2654-2670	41
245	Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. 2020 , 68, 5212-5220	5
244	Does Hormone Therapy Protect the Heart? It Is a Stressful Question. 2020 , 105,	
243	Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. 2021 , 143, 410-423	31
242	Sphingosylphosphorylcholine blocks ovariectomy-induced bone loss by suppressing Ca/calmodulin-mediated osteoclast differentiation. 2021 , 25, 473-483	2
241	Response to Letter to the Editor: "Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline". 2021 , 106, e1926-e1927	1
240	Progestogens and the Menopause. 2021 , 193-202	
239	Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use. 2021 , 12, 20420188211013917	2
238	Genistein for glycolipid metabolism in postmenopausal women: a meta-analysis. 2021 , 24, 267-274	1
237	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. 2021 , 42, 967-984	34

236	Letter to the Editor: "Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline". 2021 , 106, e1917-e1918	
235	Hormone replacement therapy - where are we now?. 2021 , 24, 3-10	13
234	Author Response: AAN Position Statement: Ethical Issues in Clinical Research in Neurology. 2021 , 96, 409-409	
233	Blackcurrant (L.) Extract Exerts Potential Vasculoprotective Effects in Ovariectomized Rats, Including Prevention of Elastin Degradation and Pathological Vascular Remodeling. 2021 , 13,	2
232	Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. 2021 , 12, 564781	6
231	C-Reactive Protein Mediates the Effect of Serum Progesterone on Obesity for Men and Postmenopausal Women in Henan Rural Cohort Study. 2021 , 14, 633-644	2
230	Evaluation of menopausal hormone therapy use in Korea (2002-2013): A nationwide cohort study. 2021 , 146, 57-62	3
229	Association of Migraine With Incident Hypertension After Menopause: A Longitudinal Cohort Study. 2021 , 97, e34-e41	3
228	The role of medications in successful aging. 2021 , 24, 505-512	0
227	The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia. 2021 , 20, 98	3
226	Estrogen activates endothelial exocytosis. 2021 , 558, 29-35	2
225	Effects of Rohrbach on RANKL-induced osteoclast differentiation and OVX rats. 2021 , 24,	1
224	Human endometrium-derived stem cell improves cardiac function after myocardial ischemic injury by enhancing angiogenesis and myocardial metabolism. 2021 , 12, 344	0
223	Closing the Gender Gap in Ischemic Heart Diseases and Myocardial Infarction. 2021 ,	1
222	Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era. 2021 ,	1
221	Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. 2021 , 28, 973-997	18
220	Synergistic Protective Effects of Resveratrol and Estradiol on Estrogen Deficiency-Induced Osteoporosis Through Attenuating RANK Pathway. 2021 , 17, 217-228	0
219	Sex Differences and Regulatory Actions of Estrogen in Cardiovascular System. 2021 , 12, 738218	3

218	Compounded Bioidentical Hormones: Myths and Realities. 2021 , 64, 793-802	1
217	Sex and Gender Aspects in Vascular Ageing - Focus on Epidemiology, Pathophysiology, and Outcomes. 2021 , 30, 1637-1646	2
216	Gender-dependent mechanisms of injury and repair. 2022 , 303-318	
215	Assessment of female sex in preclinical vascular models. 2021 , 349-385	
214	What is Pharmacoepidemiology?. 1-22	1
213	Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies. 38-51	1
212	Challenges and novel approaches in the epidemiological study of early life influences on later disease. 2009 , 646, 1-14	33
211	Clinical Pharmacology and Therapeutics of Antidepressants. 2004 , 33-117	4
210	Minority Women and Cardiovascular Disease. 2009 , 297-320	1
209	Study design: the basics. 2007 , 404, 1-17	5
208	Clinical Pharmacology and Therapeutics of Antidepressants. 2011 , 33-124	5
207	The Influence of Sex Steroids on Affairs of the Heart. 2014 , 225-231	2
206	Gender differences in anticoagulation and antithrombotic therapy. 2012 , 523-42	8
205	Patient-Oriented Research: Clinical Pathophysiology and Clinical Therapeutics. 2009 , 3-12	3
204	Epidemiology of Age-Related Macular Degeneration. 2006 , 1017-1027	5
203	Oral Contraceptives, Hormone Replacement Therapy, and Hypertension. 2007 , 865-882	2
202	Stage of Reproductive Life, Atherosclerosis Progression and Estrogen Effects on Coronary Artery Atherosclerosis. 2007 , 509-528	2
201	Postmenopausal Hormone Therapy in the 21st Century: Reconciling Findings from Observational Studies and Randomized Clinical Trials. 2007 , 619-626	2

200	Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. 2012 , 731-805	4
199	T-cell regulation of fibroblasts and cardiac fibrosis. 2020 , 91-92, 167-175	7
198	Hormone therapy and postural balance in elderly women. 2007 , 14, 1020-4	16
197	Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. 2008 , 15, 125-134	70
196	Endothelial-mediated microcirculatory responses to an acute estradiol test are influenced by time since menopause, cumulative hormone exposure, and vasomotor symptoms. 2010 , 17, 749-57	4
195	Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency. 2010 , 17, 766-71	19
194	The Timing Hypothesis remains a valid explanation of differential cardioprotective effects of menopausal hormone treatment. 2011 , 18, 230-236	24
193	Different mechanisms for benefit and risk of coronary heart disease and stroke in early postmenopausal women. 2011 , 18, 237-240	26
192	Osteoporosis in postmenopausal women: considerations in prevention and treatment: (women's health series). 2013 , 106, 698-706	29
191	Harnessing hormonal signaling for cardioprotection. 2005 , 2005, re6	11
190	Rapid progress for non-nuclear estrogen receptor signaling. 2010 , 120, 2277-9	55
189	Resveratrol as Cardioprotective Agent. 2005 , 539-555	2
188	Established risk factors account for most of the racial differences in cardiovascular disease mortality. 2007 , 2, e377	37
187	Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. 2009 , 4, e6271	55
186	Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials. 2013 , 8, e62329	19
185	Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?. 2005 , 1, 111-7	7
184	Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. 2012 , 12, 149-74	82
183	Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?. 2019 , 17, 564-572	28

182	The Role of Estradiol in Traumatic Brain Injury: Mechanism and Treatment Potential. 2020 , 22,	5
181	Natural Substance MS-10 Improves Women's Health via Regulation of Estrogen Receptor. 2016 , 45, 903-910	4
180	State of the Heart: Building Science to Improve Women's Cardiovascular Health. 2006 , 15, 556-566	26
179	Coronary Event Analysis in Breast Cancer Patients Who Received Breast-Conserving Surgery and Post-Operative Radiotherapy: a Korean Nationwide Cohort Study. 2020 , 23, 291-302	2
178	A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures. 2013 , 74, 1003-9	13
177	Patterns of medication use for the treatment of menopausal symptoms before and after the women's health initiative; implications for decision-making practices of women and women's health professionals. 2011 , 03, 416-422	1
176	Climacteric Symptoms & Hormone Therapy. 2006 , 49, 11	3
175	The Effects of Menopause on the Metabolic Syndrome in Korean Women. 2015 , 16, 2704-2712	6
174	Survey on the Consumption of the Phytoestrogen Isoflavone in Postmenopausal Korean Women. 2012 , 18, 163	8
173	The 2020 Menopausal Hormone Therapy Guidelines. 2020 , 26, 69-98	10
172	The Choice of a Comparator. 2021 , 125-146	
171	Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population. 2021 , 12, 718200	0
170	Changing Incidence and Mechanism of Pregnancy-Associated Myocardial Infarction in the State of California. 2021 , 10, e021056	0
169	Coronary Artery Disease in Women: A Comprehensive Appraisal. 2021 , 10,	2
168	The effect of tibolone treatment on fasting blood sugar, insulin, insulin resistance and endothelial function in postmenopausal women: A meta-analysis of randomized controlled trials. 2021 , 155, 111586	2
167	Gender and Its Impact on Risk Factors for Cardiovascular Disease. 2004 , 193-214	1
166	Gender Differences in Dermatology. 2004 , 1241-1245	
165	Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease. 2004 , 47, 704	2

164 Diagnosis and Treatment of Depression During Pregnancy and Lactation. **2004**, 265-296

163 Pharmaceuticals.

162 Evidence-based medicine and hormone replacement therapy. **2004**, 24, 164-5

161 Sovremennyye polozheniya po ispol'zovaniyu ZGT u zhenshchin v menopauze v ramkakh pozitsii Ispolnitel'nogo komiteta Mezhdunarodnoy Assotsiatsii po menopauze. **2004**, 1, 45-47

160 Coronary heart disease. **2004**, 104, 41S-48S

2

159 Hoofdstuk 7 Afwijkingen van de koolhydraat- en vetstofwisseling. **2005**, 153-185

158 Hypertension in the Elderly. **2005**, 579-586

157 Hormone Therapy in Postmenopausal Women. **2005**, 48, 377

156 Does Hormone Replacement Therapy Have a Future?. **2005**, 1, 5-8

155 Is bij vroegtijdige menopauze de kans op borstkanker kleiner? Wordt deze weer groter bij gebruik van HST?. **2006**, 1092-1093

154 Estrogen Dose Response in Bone Density and Bone Histology. **2006**, 171-175

153 Phytoestrogens: Food or Drug?. **2006**, 219-231

152 Zijn bij gebruik van isoflavonen bij menopauzale klachten de risico's op mammacarcinoom vergroot?. **2006**, 1034-1036

151 Psychological Stress in Women: the Stockholm Female Coronary Risk Study. **2006**, 273-277

150 Molecular mechanisms in obesity hypertension: focus on the renin-angiotensin system and the sympathetic nervous system. **2006**, 400-411

149 Women and Coronary Heart Disease. **2006**, 689-720

148 Coronary Disease in Women. **2007**, 713-727

147 Menopause. **2007**, 589-600

- 146 Thrombotic Risk of Contraceptives and Other Hormonal Therapies. **2007**, 567-580
- 145 Postmenopausal Hormone Therapy Up-to-date. **2007**, 22, 317 1
- 144 The Women's Health Initiative Data and Discussion. **2007**, 611-618
- 143 Clinical Trials in Postmenopausal Hormone Therapy. **2007**, 863-874
- 142 Cerebrovascular Disease/Transient Ischemic Attack. **2007**, 1911-1921
- 141 Mechanisms of Action of Estrogen on the Cardiovascular System. **2007**, 453-459
- 140 Morbidity and Mortality Changes with Hormone Therapy. **2007**, 627-636
- 139 Women and Coronary Heart Disease. **2008**, 71-96
- 138 Changes in lipid metabolism in postmenopausal Japanese women using hormone therapy evaluated by capillary isotachopheresis: a pilot study. **2008**, 15, 157-63 0
- 137 Sexualthormone. **2008**, 843-864
- 136 Estrogen Therapy: Prevention and Treatment of Osteoporosis. **2008**, 1687-1703 0
- 135 Hormone replacement therapy and diabetes. **2008**, 458-465
- 134 Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze: konsensus rossiyskikh kardiologov i ginekologov. **2008**, 5, 26-39 5
- 133 ACC/AHA Non-ST Elevation Myocardial Infarction Guidelines' Revision 2007: Implications for Nursing Practice. **2008**, 23, 53-56
- 132 Sexualthormone. **2009**, 835-856
- 131 Calcio e derivati della vitamina D, terapia sostitutiva, calcitonina, fluoruri, bisfosfonati. **2009**, 493-514
- 130 Klinik der Perimenopause, der Postmenopause und des Seniums. **2009**, 521-559 1
- 129 Cohort Studies. **2009**, 33-44

- 128 Treatment Guidelines Overview. **2009**, 202-216
- 127 One Case of Malignant Mixed Müllerian Tumor Developed in a Postmenopausal Woman under Hormone Therapy. **2009**, 30, 723
- 126 Prevention of Cardiovascular Disease. **2009**, 403-436
- 125 The Women's Health Initiative: Lessons for Preventive Nutrition. **2010**, 337-370
- 124 Menopause and Hormone Replacement Therapy. **2010**, 535-541 0
- 123 Natural and Surgical Menopause. **2010**, 141-169
- 122 Bone Density and Imaging of Osteoporosis. **2010**, 1261-1291 2
- 121 Sexualthormone. **2010**, 867-888
- 120 Klimakterium [hormonelle Substitution]. **2010**, 454-459
- 119 Hormone Therapy and the Risk of Venous Thromboembolism. **2010**, 1233-1235.e1 0
- 118 Chapter 12 High Blood Cholesterol. **2010**,
- 117 Vitamin E taken as capsules does not affect cataract incidence and progression. **9**, 130-131
- 116 Unstable Angina and Non-ST Elevation Myocardial Infarction. **2011**, 195-225
- 115 Exercise restores autonomic balance in menopause and after cardiovascular events. **2010**, 17, 676-7 1
- 114 Early Disease, Early Detection, Early Treatment: Some Common Threads and Some Important Problems. **2011**, 495-507
- 113 Prevention of Ischemic Heart Disease in Women. **2011**, 398-414
- 112 Management of osteoporosis. **2011**, 1975-1988.e4
- 111 Disorders of Female Orgasm. **2011**, 147-161

- 110 Cardiovascular risk factors in women and the role of sex hormones. **2011**, 10, 128-135 5
- 109 Risk-Benefit Analysis of Combination Versus Unopposed HRT in Post-Menopausal Women. **2011**, 1, 61-76
- 108 Neuroendocrine aspects of sleep apnea. **2011**, 286-299
- 107 Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development. 1
- 106 Cardiovascular Disease in Women. **2012**, 1757-1769
- 105 Relationship of Oxidative Stress with Cardiovascular Disease. **2013**, 285-313
- 104 Cardiac Ageing and Systemic Disorders. 29-43
- 103 Description of an Audio-Based Paced Respiration Intervention for Vasomotor Symptoms. **2013**, 5, 8-14 1
- 102 Semiparametric Inference on the Absolute Risk Reduction and the Restricted Mean Survival Difference. **2013**, 23-46
- 101 Oral low-dose estradiol plus norethisterone acetate with or without simvastatin in dyslipidemic and symptomatic menopausal women: A randomized clinical trial. **2013**, 05, 110-118
- 100 Environmental and Nutritional Diseases. **2013**, 269-307
- 99 Hormonersatztherapie. **2013**, 281-312
- 98 Diet and Exercise Are Potent Modulators of Cardiovascular Disease in Women. **2013**, 175-204
- 97 Menopause. **2013**, 271-286
- 96 Ovary, Uterus (Fallopian Tube, Cervix), Vagina, and Vulva. **2014**, 551-570 1
- 95 Effects of Hormones and Hormone Therapy on Cardiovascular Health in Women. **2014**, 359-377
- 94 Semiparametric Analysis of Treatment Effect via Failure Probability Ratio and the Ratio of Cumulative Hazards. **2014**, 329-351
- 93 Use of Phytoestrogens in Q̄qchi Maya Ethnomedicine. **2014**, 71-86 0

- 92 Afwijkingen van de koolhydraaten vetstofwisseling. **2015**, 229-274
- 91 Afwijkingen van de koolhydraaten vetstofwisseling. **2015**, 109-125
- 90 The Women's Health Initiative: Lessons for Preventive Nutrition. **2015**, 335-369
- 89 Management of osteoporosis. **2015**, 1663-1673
- 88 Afwijkingen van de koolhydraaten vetstofwisseling. **2015**, 161-196
- 87 Postmenopausal Hypertension and Coronary Artery Disease Risk. **2016**, 329-350
- 86 Is there any relationship between different phenotypes of metabolic syndrome and cardiovascular mortality rate?. **2016**, 5, 185 1
- 85 Veränderungen im Knochenstoffwechsel und/oder an der Knochenmatrix. **2016**, 207-295
- 84 Atherothrombotic Risk Factors and Graft Disease. **2016**, 317-339
- 83 Management of Angina. **2016**, 111-163
- 82 Investigation of the Relationship between Myocardial Infarction, Angina Pectoris, and Venous Thrombosis and Some Risk Factors in the Women Suffering from Cardiovascular Diseases with a History of Contraceptive Pills Consumption. **2016**, 10, 77-83
- 81 Maladie coronaire chez la femme. **2016**, 200, 1465-1473
- 80 MENOPAUSAL HORMONE THERAPY WITH DYDROGESTERONE: ASPECTS OF EFFICACY AND SAFETY OF ULTRA-LOW DOSES. **2017**, 92-99 3
- 79 Sex differences in gene expression in response to ischemia in the human myocardium. 0
- 78 Hormone Replacement Therapy and Postmenopausal Cardiovascular Events: A Meta-Analysis. **2019**, In Press, 0
- 77 Menopausal hormone therapy and heart disease prevention: desired or valid?. **2019**, 18, 94-106
- 76 Effects of Drugs, Phytoestrogens, Nutrients and Probiotics on Endothelial Dysfunction in the Estrogen-Deficient State. **2020**, 26, 3711-3722 3
- 75 Hormonothérapie finisante chez les femmes transgenres. **2020**, 1, 597-603

74	A Weight of Evidence Account. 2020 , 67-86	
73	Primary Prevention of Coronary Artery Disease. 2020 , 61-73	
72	Comparative Efficacy and Safety of Clonazepam versus Nortrptilline on Menopausal Symptom among Forty Plus Women: A Prospective, Open-Label Randomized Study. 2020 , 11, 120-125	
71	Peri- und Postmenopause [Diagnostik und Therapie. 2020 , 347-360	
70	Risk-Benefit Analysis of Combination vs. Unopposed HRT in Post-Menopausal Women. 1424-1440	
69	Koronarinsuffizienz und Herzinfarkt. 2005 , 3-33	
68	Klimakterium, Postmenopause und Senium. 2006 , 61-103	
67	Integrative Pain Medicine Models. 2008 , 497-545	
66	Hormonersatztherapie. 2007 , 269-289	
65	Sexualhormone. 2007 , 893-917	
64	HRT and Cardiovascular Disease in Women. 2006 , 103-119	
63	Veränderungen im Knochenstoffwechsel und/oder an der Knochenmatrix. 2008 , 211-305	
62	Sexualhormone. 2008 , 845-867	
61	Reviews Systematic and Meta-analysis. 2021 , 507-523	1
60	The effect of folic Acid on menopausal hot flashes: a randomized clinical trial. 2013 , 2, 131-40	2
59	Hormone replacement therapy is safe in women undergoing coronary artery bypass grafting. 2005 , 32, 507-14	4
58	Hormone replacement therapy after the menopause--where are we now?. 2005 , 55, 172-4	3
57	Platelet reactivity and genetics down on the pharm. 2006 , 117, 103-11; discussion 111-2	3

56	Should symptomatic menopausal women be offered hormone therapy?. 2006 , 8, 40	6
55	Inquiring minds: women's approaches to evaluating complementary and alternative therapies for menopausal symptoms. 2007 , 53, 85-90, 84	7
54	Phytoestrogens: food or drug?. 2007 , 4, 123-30	19
53	An update on hormone replacement therapy: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns. 2011 , 84, 39-42	11
52	Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. 2008 , 15, 125-32	58
51	Interviews With Two Women's Health Experts On the Use of Estrogen Therapies. 2012 , 37, 166-72	
50	An overview of cholesterol management. 2008 , 1, 39-48	10
49	Effect of black cohosh (<i>cimicifuga racemosa</i>) on vasomotor symptoms in postmenopausal women: a randomized clinical trial. 2013 , 2, 105-13	11
48	Menopause care for obese and diabetic women. 2009 , 1, 142-52	1
47	Causal inference and evidence-based recommendations in occupational health and safety research. 2020 , 46, 554-556	
46	Predicting the risk of atherosclerotic cardiovascular disease among adults living with HIV/AIDS in Addis Ababa, Ethiopia: A hospital-based study. 2021 , 16, e0260109	0
45	Sex differences in eicosanoid formation and metabolism: A possible mediator of sex discrepancies in cardiovascular diseases. 2021 , 108046	2
44	Menopause Hormone Therapy. 2022 , 121-143	
43	The Interaction of Menopause and Chronic Disease. 2022 , 91-120	1
42	Update on hormone therapy for the management of postmenopausal women.. 2022 , 16,	1
41	Causal inference and evidence-based recommendations in occupational health and safety research. 2020 , 46, 554-556	
40	Safety and Feasibility of Early Oral Nutrition after Endoscopic Treatment for Patients with Liver Cirrhosis: A Historical-prospective, Comparative-Effectiveness Study.. 2022 ,	
39	Cardiovascular Disease in Women Update: Ischemia, Diagnostic Testing and Menopause Hormone Therapy.. 2021 ,	3

38	Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: A pooled analysis of 2917 postmenopausal women.. 2022 , 344, 13-19		1
37	Blood Pressure Trajectories Through the Menopause Transition: Different Paths, Same Journey.. 2022 , 130, 323-325		
36	Sex and Gender Differences in Lung Cancer and Chronic Obstructive Lung Disease.. 2021 ,		0
35	Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. 2021 , 14, e007903		0
34	Hormone Therapy in the Transgender Patient. 2022 , 157-162		
33	Safety and efficacy of compounded bioidentical hormone therapy (cbHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.. 2022 , 29, 465-482		1
32	Estradiol and Estrogen-like Alternative Therapies in Use: The Importance of the Selective and Non-Classical Actions.. 2022 , 10,		2
31	Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for Coronary Artery Disease: JACC Focus Seminar 3/7.. 2022 , 79, 1407-1425		1
30	Early menopause is associated with increased risk of retinal vascular occlusions: a nationwide cohort study.. 2022 , 12, 6068		0
29	Infertility and Risk of Heart Failure in the Women's Health Initiative.. 2022 , 79, 1594-1603		2
28	Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials.. 2022 , 106762		1
27	Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type-2 Diabetes: The Prescriptive Approach in the Real World.. 2021 , 12, 140		1
26	Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor.. 2022 , 13, 876777		
25	Effects of Endocrine Disorders on Lipids and Lipoproteins. 2022 , 101667		0
24	Steroid profiling in brain and plasma of adult zebra finches following traumatic brain injury. <i>Journal of Neuroendocrinology</i> ,	3.8	0
23	CARDIOVASCULAR PATHOLOGY IN WOMEN: RISKS AND CHANCES (literature review). <i>Problemy Zdorov'ya Biologii</i> , 2013 , 53-58	0.2	
22	12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation. <i>Frontiers in Pharmacology</i> , 13,	5.6	1
21	Oral Contraceptives, Hormone Replacement Therapy, and Stroke Risk. <i>Stroke</i> ,	6.7	2

20	Comparison of Thrombocyte Volume, Thrombocyte/Lymphocyte and Neutrophil/Lymphocyte Ratios According to Body Mass Index in Postmenopausal Patients and The Effect of These Results On Cardiovascular Risk and Hot Flashes. 2022 , 4, 70-76		
19	Management of Dyslipidemia in Endocrine Diseases. <i>Endocrinology and Metabolism Clinics of North America</i> , 2022 ,	5.5	1
18	Uterus: A Unique Stem Cell Reservoir Able to Support Cardiac Repair via Crosstalk among Uterus, Heart, and Bone Marrow. <i>Cells</i> , 2022 , 11, 2182	7.9	
17	Exemestane for Breast Cancer Prevention: A Feasible Strategy?. 2005 , 11, 918s-924s		0
16	Transdermal Absorption of Sclareol, an Active Ingredient in Clary Sage Oil: A Complementary and Alternative Medicine for Menopausal Symptoms. 2022 , 2, 304-312		0
15	Risk Factors for Ischemic Heart Disease in Women. 2022 , 163-191		0
14	Measuring Change. 2022 , 1445-1465		0
13	Transgender Medicine and Risk of Venous Thromboembolism. 2022 , 42, 301-307		0
12	Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons. 2022 , 328, 1747		6
11	Menopause, Hormone Therapy and Cardiovascular and Cerebrovascular Disease. 2008 , 37, 54-62		1
10	Avicularin Alleviates Osteoporosis in Ovariectomized Mice by Inhibiting Osteoclastogenesis through NF- κ B Pathway Inhibition.		0
9	Tests and Interventions. 2022 , 55-69		0
8	What Covid-19 Has Taught Us (or Not). 2022 , 177-182		0
7	17 β -Estradiol Promotes Sex-Specific Dysfunction in Isolated Human Arterioles.		0
6	Physiological and Clinical Considerations of Geriatric Patient Care. 2022 ,		0
5	What may be the best menopausal hormone treatment?.		0
4	Cardiometabolic health, menopausal estrogen therapy and the brain: how effects of estrogens diverge in healthy and unhealthy preclinical models of aging. 2023 , 101068		0
3	Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?. 2023 , 147, 597-610		0

- 2 Reproductive Changes from Puberty to Menopause and the Effects of the Menstrual Cycle on Bone Formation and Bone Loss. **2023**, 69-84 ○
- 1 Evidence-Based Cardiovascular Imaging. **2023**, 16, 405-407 ○